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The majority of cancer patients die from metastasis. To achieve metastasis, tumor 
cells must first survive and then proliferate to form colonies. Compelling data have 
shown the indispensable participation of host microenvironment for metastasis. Bone 
marrow derived myeloid cells sculpt a tumor-promoting microenvironment in the 
premetastatic organs prior to tumor cell arrival. However, the molecular mechanisms for 
this “seed and soil” hypothesis are unclear.  
Here we report that CCL9 was significantly produced and secreted by 
Gr-1+CD11b+ cells when co-cultured with tumor cells, and in the premetastatic lung. 
CCL9 knockdown (KD) in myeloid cells decreased metastasis, and this process signaled 
through its sole receptor CCR1. Overexpression of CCR1 lost the metastasis-promoting 
function in the context of CCL9 KD. CCL9 enhanced tumor cell survival in the 
premetastatic organs. The underlying molecular mechanisms included activation of cell 
survival factors phosphorylated AKT and BCL-2, as well as inhibition of Poly 
(ADP-ribose) polymerase (PARP)-dependent apoptosis pathway. Additionally, 
CCL9/CCR1 had autocrine effects, which enhanced CCL9 secretion and the survival of 
Gr-1+CD11b+ cells. 
We found that CCL9 was a key effector of myeloid transforming growth factor β 
(TGF-β) pathway that promotes metastasis. Decreased metastasis in mice with myeloid 
specific TGF-β receptor II deletion (Tgfbr2MyeKO) correlated with lower CCL9 expression 
in TGF-β deficient myeloid cells. Importantly, CCL9 over-expression in theses cells 
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rescued metastasis deficiency. Furthermore, inhibition or KD of p38, a downstream 
molecule in TGF-β singling pathway, decreased CCL9 expression in wild type but 
not TβRII-deficient Gr-1+CD11b+ cells.  
Our findings likely had clinic significance as human data paralleled those from 
mouse studies. CCL23, the human orthologue for mouse CCL9, was elevated in the 
supernatant by peripheral blood mononuclear cells (PBMCs) when co-cultured with 
human tumor cells. Publicly available databases showed a negative correlation between 
CCL23/CCR1 expressions and metastasis free survival of cancer patients. Our work 
indicates that CCL9 may serve as a target for treating cancer patients with metastasis. 
This approach may bypass the complexity of TGF-β treatment that results from its dual 
pro- and anti-cancer function. 
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Metastasis is a question of life or death. Cancer is now the leading cause of death. 
According to the newest report from the World Health Organization (WHO), there were 
8.2 million cancer-related deaths in 2012 worldwide. It is estimated that there were 
1,665,540 new cases of cancer and 585,720 deaths caused by cancer in the United States 
in 2014 (Siegel et al., 2014). Metastasis is an ominous feature of tumor progression and 
accounts for over 90% of cancer-associated deaths (Mehlen and Puisieux, 2006). Thus, 
understanding and developing methods to target metastasis is important for effective 
therapies of cancer patients.  
Metastasis is a process in which tumor cells spread from a primary tumor of origin 
and colonize to the distant organs. The metastasis cascade often occurs in the following 
order (Fig. 1). (1) Local invasion. Tumor cells must acquire the ability to migrate and 
invade in order to break away from the primary tumor site. These abilities are affected by 
genetic and epigenetic changes in tumor cells, as well as the influence of the tumor 
microenvironment. (2) Intravasation. Tumor cells enter blood vessels, which are 
established through tumor vascularization. This step normally involves epithelial to 
mesenchymal transition (EMT). (3) Circulation. Cancer cells traveling through the 
circulatory system are dubbed circulating tumor cells (CTCs). CTCs circulate through 
blood vessels until they reach the secondary organ. They display properties of 
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anchorage-independent survival. (4) Extravasation. CTCs exit the blood vessels once 
successfully lodge in the distant tissue and subsequently invade the foreign tissue. Tumor 
cell mesenchymal to epithelial transition (MET) is critical for extravasation. It has been 
shown that CTCs can also proliferate inside of the microvessels (Wong et al., 2002). (5) 
Colonization. Tumor cells proliferate in the distant organ and form tumor nodules.  
Tumor-stroma interactions are indispensable participants in the metastatic process. 
Of interest, cancer cells often do not need additional genomic alterations in order to 
establish metastatic colonies when compared to the cancer cells at the primary tumor site 
(Vanharanta and Massague, 2013). In fact, gene expression orchestrated by 
microenvironmental cues play a fundamental role in the metastatic processes. Myeloid 
cells have been implicated in supporting cancer metastasis (Grivennikov et al., 2010; 
McAllister and Weinberg, 2010). The functionality of these cells involves suppression of 
host anti-tumor immunity (Gabrilovich et al., 2012; Pang et al., 2013), promotion of 
tumor angiogenesis (Yang et al., 2004), enhanced tumor cell extravasation (Qian et al., 
2011), migration and invasion (Kitamura et al., 2007), and premetastatic niche formation 






Figure 1. The metastasis cascade.  
Metastasis can be envisioned as a process that occurs in two major phases: (i) physical 
translocation of cancer cells from the primary tumor to a distant organ and (ii) 
colonization of the translocated cells within that organ. (A) To begin the metastatic 
cascade, cancer cells within the primary tumor acquire an invasive phenotype. (B) Cancer 
cells can then invade the surrounding matrix and move toward blood vessels, where they 
intravasate to enter the circulatory system. (C) CTCs circulate through blood vessels and 
arrive at the distant organ, which serves as their primary means of passage to distant 
organs. (D) At the secondary organ, CTCs exit the blood vessels and invade the local 
tissues of a hostile microenvironment. (E) At the distant organ, cancer cells must be able 
to evade the innate immune response and to survive as a single cell or as a small cluster 
of cells. (F) Cancer cells adapt to the foreign microenvironment and initiate proliferation 
to develop into an active macrometastatic deposit. Figure adapted from Chaffer & 








Tumor cell survival is a rate-limiting step in metastasis 
Tumor cell survival is a rate-limiting step in cancer metastasis. Tumor cells must 
firstly evade apoptosis, in order to survive and proliferate in the distant organ. This is 
supported by the fact that in human patients, the expression of pro-apoptotic 
Bcl-2-associated X protein (BAX) negatively correlates with metastasis, whereas 
anti-apoptotic protein B-cell lymphoma-2 (BCL-2) positively associates with metastasis 
(Krajewski et al., 1995; Le et al., 1999). Highly metastatic tumor cells also exhibit a 
significantly lower level of apoptosis in the distant organ compared to none or low 
metastatic tumor cells (Fidler, 1975; Hong et al., 2012), and loss or down regulation of 
apoptosis directly impacts metastasis in different cancers (Cotter, 2009; Lowe and Lin, 
2000). Blocking tumor cell apoptosis increases metastasis (Del Bufalo et al., 1997; 
Owen-Schaub et al., 1998), whereas promoting tumor cell apoptosis decreases metastasis 
(Medina-Ramirez et al., 2011; Owen-Schaub et al., 1998). Additionally, activation of the 
cell survival molecules, such as Src or AKT, directly inhibits tumor cell apoptosis and 
promotes tumor cell survival (Zhang et al., 2009). Targeting tumor cell apoptosis is a 
promising strategy for cancer treatment (Fesik, 2005).  
Despite the fact that apoptotic molecules within tumor cells play fundamental roles 
in tumor cell survival, recent studies have found that host cells also contribute to 
increased tumor cell survival (Lazennec and Richmond, 2010; Steeg, 2006). For example, 
bone marrow stromal cells isolated from cancer patients secrete osteoprotegerin (OPG), 
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which protects breast cancer cells from TRAIL-induced apoptosis (Neville-Webbe et al., 
2004). In mouse models, macrophages express α4 intgrin (Chen et al., 2011) and 
Gr-1+CD11b+ cells secrete S100A8/9 (Acharyya et al., 2012) to inhibit tumor cell death 
at the metastatic site.  
Thus, identifying factors responsible for tumor cell survival, especially those from 
host cells, may provide an important insight for understanding cancer biology and 
facilitating the design of effective cancer treatments.  
 
Microenvironment in the premetastatic organ 
The microenvironmental cue in a distant organ (premetastatic organ) is critical for 
metastatic colony establishment. Premetastatic lung is the lung microenvironment prior to 
the arrival of tumor cells. Tumors modulate the premetastatic lung environment and build 
up a “soil” that is favorable to the seeding of tumor cells. Developing a premetastatic 
tissue includes changes in inflammatory responses, matrix remodeling, and other 
bioactive oncogenic molecules, such as vascular endothelial growth factor (VEGF) and 
matrix metalloproteinases (MMPs) (Kaplan et al., 2005). The “seed and soil” hypothesis 
is firstly proposed by Steven Paget, who theorizes that the congenial microenvironment is 
required for malignant tumor cells to colonize in the secondary organ (Paget, 1989). In 
the battle with cancer, significant efforts have been devoted to understanding the behavior 
of tumor cells. Cancer biologists have successfully identified the important roles of tumor 
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suppressor genes such as p53 and retinoblastoma protein (Rb), as well as oncogenes such 
as myc and Src. However, targeting these molecules in tumor cells has only succeeded in 
a portion of cancer patients, and this may due to individualized host immunity. As a result, 
understanding the “soil” of the tumor microenvironment is greatly needed, as it may shed 
insight into new methods of cancer treatment as an addition to the current ones.  
Hematopoietic cells, especially myeloid cells, play a key role in the premetastatic 
organs. For example, bone marrow-derived hematopoietic progenitors that reside in the 
premetastatic lung secrete high level of VEGF, which attracts VEGF receptor 1 
expressing (VEGFR1+) myeloid cells to form a premetastatic niche for the incoming 
tumor cells (Kaplan et al., 2005). Mac-1+ myeloid cells are recruited by S100A8/9 (S100 
calcium binding protein A8/9) in the premetastatic lung to promote tumor migration and 
invasion (Hiratsuka et al., 2006). Also, CD11b+ cells are recruited by Lysyl oxidase 
(LOX) that is secreted by hypoxic tumor cells, and in respond to produce matrix 
metalloproteinase-2 (MMP2) to enhance tumor cell invasion by cleaving collagen (Erler 
et al., 2009). In the premetastatic brain, Gr-1 neutralization decreases the myeloid cell 
population and the subsequent brain metastasis (Liu et al., 2013).  
Our research confirms the supportive function of hematopoitic cells in metastasis 
and demonstrates that a specific myeloid cell subset, Gr-1+CD11b+ cells of 
tumor-bearing mice, build up an inflammatory, proliferative, and immune suppressive 
premetastatic lung microenvironment (Yan et al., 2010). Gr-1+CD11b+ cells sculpt the 
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lung by altering the expression profile of cytokines. We have found reduced type I 
cytokine interferon-gamma (IFN-γ) and increased expression of type II cytokines (Yan et 
al., 2010). Additionally, we have observed an increased MMP9 expression in the 
premetastatic lung, which leads to blood vessel leakage, and facilitates tumor cell 
extravasation (Yan et al., 2010). 
However, whether myeloid cells secrete cytokines into the premetastatic lung 
microenvironment to promote tumor cell survival and the consequential lung metattasis 
need to be carefully investigated. 
 
Gr-1+CD11b+ cells promote metastasis 
Gr-1+CD11b+ cells are also known as Myeloid Immune Suppressor cells (MISCs) 
or Myeloid Derived Suppressor cells (MDSCs). In mice, it is a heterogeneous cell 
population expressing granulocyte marker Ly6G, monocyte marker Ly6C, and 
macrophage marker F4/80, and all of these cells express the macrophage lineage marker 
CD11b. In cancer patients, immature myeloid cells typically express myeloid markers 
CD11b/CD33/CD34. These cells do not express the lymphocyte marker CD14 or 
leucocyte antigen HLA-DR, and can vary in their expression of CD15 and other markers 
(Ostrand-Rosenberg and Sinha, 2009).  
The Gr-1+CD11b+ cell type is a good model to study the function of immature 
myeloid cells under cancer conditions. In humans, immature myeloid cells are 
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overproduced in the peripheral blood of patients with neck/head, breast, and lung cancer 
(Almand et al., 2001). In mice, Gr-1+CD11b+ cells are significantly increased in the 
spleen and bone marrow of tumor-bearing mice and become the main population of 
immature myeloid cells (Youn et al., 2008). Under tumor conditions, these myeloid cells 
are prevented from further differentiating into mature macrophages or dendritic cells 
(DCs) to exert immune responses. Instead, they remain in their immature status and 
become immune suppressive (Gabrilovich and Nagaraj, 2009).  
Gr-1+CD11b+ cells are well characterized for their function in modulating the 
immune response (Fig. 2). They are known to regulate T cell function through following 
four mechanisms. (1) Down regulating TCR (T cell receptor) complex and T cell 
proliferation by secreting arginase and iNOS (inducible nitric oxide synthase) to deplete 
L-arginine as an important nutrient for T cells (Bronte and Zanovello, 2005). (2) 
Inhibition of normal cytokine production from T cells by producing ROS (reactive 
oxygen species) like H2O2 (Schmielau and Finn, 2001). (3) Depletion of cysteine that is 
essential for T cell activation (Srivastava et al., 2010). (4) Activation/expansion of Treg 
(regulatory T cell) populations (Pan et al., 2010). Gr-1+CD11b+ cells also interfere with 
lymphocyte trafficking and viability by expressing ADAM17 (disintegrin and 
metalloproteinase domain-containing protein 17), which cleaves L-selectin on the naive 
CD4+ and CD8+ T cells (Schmielau and Finn, 2001).  
Other than T cells, Gr-1+CD11b+ cells diminish the cytotoxicity of natural killer 
(NK) cells by inhibiting perforin production (Liu et al., 2007). They also inhibit Th1 
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cytokine IL-12 production from macrophages by secreting high level of Th2 cytokine 
IL-10 (Sinha et al., 2007). Additionally, Gr-1+CD11b+ cells inhibit dendritic cell 
differentiation by S100A9 production, thus diminish the presence of APC (antigen 
presenting cells) (Cheng et al., 2008). 
In addition to their immune modulating function, Gr-1+CD11b+ cells directly 
promote tumor metastasis. Those cells are found at the tumor invasive front and secrete 
high levels of VEGF to enhance metastasis by promoting tumor angiogenesis (Yang et al., 
2004). Gr-1+CD11b+ cells are also recruited in the premetastatic lung to build up a 
tumor-favorable lung microenvironment (Yan et al., 2010). However, the mechanisms by 











Figure 2. Gr-1+CD11b+ cells suppress anti-tumor immunity through a variety of 
mechanisms.  
T cell activation is suppressed by cysteine deprivation, Treg induction, as well as 
arginase, iNOS, and ROS produced by Gr-1+CD11b+ cells. Innate immunity is impaired 
by the suppression of NK cell cytotoxicity, and by the up-regulation of IL-10, which in 
turns decreases macrophage produced IL-12. Antigen presentation is limited by the 
expansion of Gr-1+CD11b+ cells at the expense of DCs. MDSCs: Gr-1+CD11b+ cells; 
NK: natural killer cells; DC: dendritic cells, Treg: T regulatory cells. Figure adapted from 








4T1 mammary tumor and B16 melanoma study models 
In this study, we focus on two tumor models: breast cancer and melanoma. Breast 
cancer is the fifth most common cancer causes deaths worldwide. In the United States, 
according to 2014 estimate, breast cancer has the highest incidence (29%) and it is the 
second most common cause of death (15%) in females. Melanoma has the 5th highest 
incidence (14%) and it is the 8th most common cause of death (2%).  
The 4T1 mammary tumor and B16 melanoma models share many characteristics 
with human breast cancer and melanoma, respectively, particularly in their ability to 
metastasize to the lungs. The 4T1 model includes four isogenic tumorigenic lines, all of 
which originates from one spontaneous murine mammary gland tumor in a BALB/cfC3H 
mouse (Dexter et al., 1978). Ordered from lowest to highest metastatic capability, they 
are the 67NR, 168FARN, 4TO7 and 4T1 cell lines. 67NR forms primary tumors; 
168FARN disseminates from the primary tumors and can form metastasis in lymph nodes; 
4T07 metastasizes to the lungs but does not form colonies; and 4T1 can finish all steps 
and form metastatic nodules mainly in the lung but also in other organs including the 
bone and brain (Aslakson and Miller, 1992).  
The B16 model includes 11 isogenic tumorigenic cell lines number sequentially 
from B16F1, B16F2… to B16F11, all of which originate from one spontaneous murine 
melanoma in a C57BL/6 mouse. It has been determined that cell lines of later passages 
have higher metastatic capabilities compared to earlier passages (Fidler, 1975). To 
produce these cell lines, cells were injected into animals through the tail vein and 
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pulmonary nodules were collected 3 weeks later. Harvested cells were then cultured until 
confluent and injected back into mice. This procedure was repeated 10 times, with B16F1 
representing the line originating from the first passage and each consecutive passage 
labeled with the succeeding number (Fidler, 1975). 
The B16BL6 cell line was generated by injecting B16F10 cells into the urinary 
bladders of C57BL/6 mice. The bladders were collected and cultured on a semi-solid agar 
in vitro. Tumor cells that invade into the agar through the bladder wall were then 
recovered and established as a cell line. This was repeated 8 times, with B16BL1 
representing the first passage and each additional passage numbered consecutively. 
Compared with B16F10, B16BL6 exhibited a higher invasive capability and an increased 
frequency of spontaneous metastasis (Poste et al., 1980). In this study, we will use 











Transforming growth factor beta (TGF-β): pro-/anti-tumor functions and pathways 
TGF-β acts both as a tumor suppressor and a tumor promoter. TGF-β signaling is a 
master regulator for a number of biological processes. In normal cells, TGF-β is 
important for cell growth, differentiation, proliferation, and migration. Under tumor 
conditions, TGF-β regulates tumor initiation, progression, and metastasis (Bierie and 
Moses, 2006). Alterations of TGF-β receptor I (TβRI), TβRII, and the SMADs are found 
in multiple human cancers. These alterations include deletion, mutation, down regulation 
of molecules that activate this pathway, or up regulation of molecules that inhibit this 
pathway (Levy and Hill, 2006). In mouse models, genetic deletion or knockdown of the 
TGF-β receptors and SMADs often results in a more malignant tumor phenotype (Yang 
et al., 2010). However, TGF-β also exhibits a tumor-promoting function. High TGF-β 
activity of glioma cells associates with the poor prognosis of patients (Bruna et al., 2007). 
Overexpression of TβRI or TGF-β1 accelerates metastasis in the PyMT (polyomavirus 
middle T antigen)-induced mammary tumor-bearing mice (Muraoka-Cook et al., 2004; 
Siegel et al., 2014).  
The TGF-β pathway is activated upon the binding of TGF-β ligand to receptor. 
There are three TGF-β isoforms: TGFβ1, TGFβ2, and TGFβ3. TGFβ1 is expressed in 
epithelial, endothelial, hematopoietic, and connective tissue cells; TGFβ2 is expressed in 
epithelial and neuronal cells; and TGFβ3 is expressed primarily in mesenchymal cells 
(Achyut and Yang, 2011). TGF-β ligands signal through TβRI, TβRII, and TβRIII. Seven 
TβRI and five TβRII members have been previously described and they all contain a 
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serine/threonine kinase domain within the cytoplasmic domain. Both TGFβ1 and TGFβ3 
bind TβRII with high affinity whereas TGFβ2 can only bind TβRII (Bierie and Moses, 
2006).  
The variety of downstream pathways may explain the dual function of TGF-β. 
TGF-β signaling pathways include both the canonical SMAD-dependent pathway and the 
non-canonical SMAD-independent pathway. Upon the binding of TGF-β ligand to the 
TβRII homodimer, TβRI homodimer is recruited and phosphorylated by TβRII. The TβRI 
and TβRII heteromeric signaling complex recruits and phosphorylates the SMAD2/3 
complex, which then binds SMAD4 and translocates into nucleus to regulate gene 
transcription. Smad7 is a negative regulator that inhibits the phosphorylation of the 
SMAD2/3 complex (Nakao et al., 1997). In addition, non-canonical TGF-β signaling 
pathways include phosphoinositol-3 kinase (PI3K), mitogen-activated protein kinase, and 
small guanosine triphosphatase pathways. These pathways are most often implicated in 





Figure 3. TGF-β pathways. 
TGF-β ligands signaling through TGF-β receptors activates the canonical 
SMAD-dependent pathway. It also activates non-canonical SMAD-independent signaling 
pathways, such as mitogen-activated protein kinase, PI3 kinase, and small guanosine 
triphosphatase. These pathways are implicated in EMT, tumor cell motility, and 
migration. cyD, cyclin D; cyE, cyclin E; GSK3, glycogen synthase kinase 3; MEKK1, 
mitogen-activated protein kinase kinase kinase 1; MKK4, mitogen-activated protein 
kinase kinase 4; MLK3, mixed lineage kinase 3; mTOR, mammalian target of rapamycin; 
myc, myelocytomatosis oncogene; PI3K, phosphatidylinositol 3-kinases; Rb, 
retinoblastoma; RhoA, ras homolog gene family, member A; ROCK, rho-associated 
protein kinase; TAK1, TGF-β activated kinase 1. Figure adapted from Achyut and Yang, 
Gastroenterology. 2011 Oct;141(4):1167-78. doi: 10.1053/j.gastro.2011.07.048. Epub 







TGF-β and metastasis 
TGF-β regulates metastasis through different mechanisms. For instance, TGF-β has 
an immunosuppressive function, particularly, TGF-β activates Treg and inhibits cytotoxic 
T cells (Blobe et al., 2000; Thomas and Massague, 2005). TGF-β also promotes EMT 
and inhibits MET (Xu et al., 2009). In addition, TGF-β enhances angiogenesis as 
neutralization down regulates whereas TGF-β1 increases blood vessel formation 
(Tuxhorn et al., 2002).  
It has been reported that TGF-β is a cell type-dependent metastasis promoter but 
can also function as a metastasis suppressor. Large amount of evidence suggest that 
TGF-β signaling in epithelial cells (Forrester et al., 2005; Kitamura et al., 2007), 
fibroblasts (Hembruff et al., 2010), and T cells (Kim et al., 2006) serves as a metastasis 
suppressor, as its deletion in these cell types promotes tumor development and 
progression. Interestingly, unlike in the cell types discussed above, myeloid specific 
TGF-β promotes metastasis, as deletion of TβRII in these cells significantly decreases 
lung colonization (Pang et al., 2013). 
Chemokines and cytokines are key effectors in the cell-type dependent TGF-β 
regulation of tumor metastasis. The chemokine profile of human breast tumors due to a 
loss of epithelial TGF-β signaling correlates with poor prognosis (Bierie et al., 2009). In 
mouse models, epithelial TGF-β blocks the production of chemokines that are critical for 
the recruitment of inflammatory cells to the tumor microenvironment and the resulting 
carcinoma-immune cell interactions (Bierie et al., 2009; Ijichi et al., 2011; Yang et al., 
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2008a). Fibroblast TGF-β suppresses hepatocyte growth factor (HGF) and CCL2 
expression, which are important for epithelial cell proliferation and survival (Bhowmick 
et al., 2004; Hembruff et al., 2010). Loss of TGF-β signaling in T cells promotes the 
expression of Th2 cytokines, which further promote stromal cell expansion (Kim et al., 
2006). On the other hand, myeloid TGF-β inhibits type I cytokine IFN-γ and promotes 
type II cytokines TGFβ1, arginase1, and iNOS to enhance metastasis (Pang et al., 2013). 
In addition, TGF-β has global effects in regulating cytokine expression. It enhances the 
production of chemoattractants S100A8/9 in the premetastatic lung to promote tumor cell 
migration, as TGF-β neutralization in vivo decreases both S100A8/9 and metastasis 














MATERIALS AND METHODS 
Cell lines and cell culture 
Murine mammary tumor cell lines 67NR, 168FARN, 4T07, 4T1, 67NR-GFP, 
4T1-GFP, 4T1-luciferase, melanoma cell lines B16F1, B16F1-GFP, B16BL6, B16F10, 
mouse macrophage cell line RAW264.7, and neutrophil cell line 32DCl3 (ATCC 
CRL-11346), as well as human breast cancer cell lines MDA-MB-231, MDA-MB-435, 
human melanoma cell lines A375S2, SK-MEL-28, and human lung cancer cell line H460, 
were maintained per standard cell culture techniques. 67NR-GFP, 4T1-GFP, B16F1, 
B16F10, B16F1-GFP, A375S2, and SK-MEL-28 were gifts from Drs. Chand Khanna, 
Glenn Merlino, and Shioko Kimura (NCI). 67NR, 168FARN, 4T07, 4T1, 67NR-GFP, 
4T1-GFP, 4T1-luciferase, B16F1, B16F1-GFP, B16BL6, B16F10, RAW264.7 were 
cultured in DMEM (Gibco, 11995-065). H460, MDA-MB-231, MDA-MB-435, A375S2, 
and SK-MEL-28 were cultured in RPMI (A10491-01). 32DCl3 was cultured in glucose 
enriched RPMI (Gibco, 22400) with 0.4 ng/ml IL-3 (Gibco, PMC0034). All culture 
media contained 10% FBS (Gibco, 10091-148) and 1x Antibiotic-Antimycotic (Gibco, 
15240-062). Cells were passaged using typsin-EDTA (Gibco, 25200-056). All cell lines 






Six to eight week old female BALB/c and C57BL/6 were purchased from NCI 
Fredrick. Tgfbr2MyeKO and Tgfbr2Flox control mice were produced as previously described 
(Pang et al., 2013). In brief, myeloid specific promoter LysM driven Cre was specifically 
expressed in myeloid cells, which recognized and removed sequence between two LoxP 
sites in the exon 2 of TβRII. p38 dominant negative mice were gifts from Dr. Albert J. 
Fornace Jr (Georgetown University). All animal studies were approved by the National 
Cancer Institute Animal Care and Use Committee. 
 
Spontaneous and experimental metastasis models 
For spontaneous orthotopic metastasis assays, mammary tumor 4T1 cells (5×105) 
were injected into the #2 mammary fat pad (MFP); B16F10 melanoma cells (1×106) were 
injected subcutaneously. For experimental metastasis assays, 67NR-control/67NR-CCR1 
cells (5×105 or 1×106), 67NR, 4T1 cells (5×105), and B16F1-control/B16F1-CCR1 cells 
(1×106) were injected into the tail vein (TVI) of recipient mice. For the co-injection 
experiment, tumor cells were injected with Gr-1+CD11b+ (1×106 or 1.5×106) or 
RAW264.7 cells (2×105).  
 
Primary tumor size and lung metastasis evaluation 
Tumor size was measured twice a week using calipers beginning on day 8 after 
tumor inoculation, and the tumor size was calculated as Volume= (Width)2 × Length/2. 
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The amount of lung metastasis was evaluated using a whole lung mounting procedure as 
previously described (Jessen et al., 2004), by lung weight, or H&E staining of butterfly 
sections. In brief, lungs were firstly fixed in Formalin (VWR, BDH0502) overnight, 
dehydrated and rehydrated, and last stained with hematoxylin (Sigma, MHS80). One 
butterfly section was obtained from each mouse, and at least 5 mice were evaluated for 
each experimental group. 
 
In vivo bioluminescence imaging 
Mice were injected with D-luciferin intraperitoneally (Caliper Life Sciences, 100 μl 
of 10 mg/ml) 15 minutes before imaging. Luminescent signals were detected using an 
IVIS-SPECTRUM in vivo photon-counting device (Caliper Life Sciences). Images were 
quantified as photon counts/second using the Living Image software (Caliper Life 
Sciences). 
 
Single cell videomicroscopy (SCVM) for evaluating tumor cell survival 
Mice were euthanized and lungs were removed 6 hours after tail vein injection of 
GFP labeled tumor cells (5×105) together with Gr-1+CD11b+ (1.5×106) or RAW264.7 
cells (2×105). Images were normalized to the basal signal obtained from lungs 1 hour 
after tail vein injection. Lungs were observed under the fluorescent microscope. 10 
random pictures at 20× magnification were taken and analyzed as fluorescence signal per 
field by OpenLab software (Improvision) or ImageJ. For extravasation experiment, mice 
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were injected with 100 μl of 12.5 μg/μl 70,000 MW tetramethylrhodamine (Invitrogen, 
D1818). The lungs were imaged under a Zeiss 510 NLO confocal microscope. The 
images were analyzed with Zeiss ZEN software. 
 
Ex vivo pulmonary metastasis assay (PuMA) 
GFP labeled tumor cells (5×105) were co-injected with sorted Gr-1+CD11b+ cells 
(1.5×106) or RAW264.7 cells (2×105) through the tail vein. The mice were euthanized 5 
minutes after injection, and their lungs were infused with an agarose medium mixture as 
previously described (Mendoza et al., 2010). The lung sections (1-2mm thick) were 
placed on Gelfoam (Pfizer-Pharmacia & Upjohn Co., 09-0315-08) and cultured for 1-2 
weeks. LEICA-DM IRB fluorescent inverted microscope (Leica) and Retiga-EXi Fast 
1394 Mono Cooled CCD camera (QImaging) were used to capture GFP positive cells at 
10× or 2.5× magnification. The GFP florescence was obtained and analyzed using 
OpenLab software (Improvision) or ImageJ (Mendoza et al., 2010). The florescence 
intensity per field was quantified, normalized to day 0 signal, and presented as metastasis 
survival index. Three to six lung sections for each mouse and a total of 3-4 mice were 
evaluated for each experimental group. 
 
Immunofluorescence (IF) staining and TUNEL assay 
Paraffin-embedded lung sections or chamber slides with tumor cell culture were 
incubated with primary antibodies for GFP (Santa Cruz, SC-8334) or PAR (BD 
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Pharmingen, 550781). Alexa flour 488 or 594 secondary antibodies were used for 
detection (Invitrogen). For Terminal deoxynucleotidyl transferase dUTP (TUNEL) assay 
(Roche Applied Science, 11684795910), lungs were removed 6 hours after tail vein 
co-injection of GFP labeled tumor cells (5×105) with Gr-1+CD11b+ (1.5×106) or 
RAW264.7 cells (2×105). The lungs were fixed and Paraffin-embedded for sectioning. 
TUNEL was performed according to the manufacturer’s protocol. The slides were then 
mounted with Prolong Gold antifade reagent with DAPI (Invitrogen, P36931) and 
examined using fluorescence microscopy.  
 
Single cell suspension 
Single cell suspensions were made from spleens, peripheral blood (Yang et al., 
2004), and lung tissues (Ljung et al., 1989) of normal and 4T1 tumor-bearing mice. 
Briefly, spleenocytes were collected by direct smashing with a 3 ml syringe plunger into 
a 40 μm cell strainer (BD Pharmingen). The lungs were firstly minced into small pieces, 
then incubated for 1 hour at 37°C in a digesting cocktail. The digesting cocktail included 
1.5 mg/ml collagenase (CD130), 1 mg/ml typsin (T9201), 0.2 mg/ml DNase (D5025), 
and 0.0875 mg/ml hyaluronidase (H3506). All reagents were purchased from Sigma and 




Flow cytometry and cell sorting (FACS and MACS) 
Cells were labeled with fluorescence-conjugated antibodies: Gr-1, CD11b, Ly6G, 
Ly6C, F4/80, AnnexinV, 7AAD. All antibodies listed above were purchased from BD 
Biosciences. CCR1 (FAB5986A) and isotype control (IC013A) were purchased from 
R&D systems. For flow cytometry analysis, cells were run on a FACS Calibur or Fortessa 
flow cytometer (BD, San Jose, CA) and analyzed using FlowJo. For sorting, 
Gr-1+CD11b+ cells, Ly6G+CD11b+ cells, Ly6C+CD11b+ cells, and F4/80+CD11b+ 
cells were sorted from spleens of 4T1 tumor-bearing mice by FACSAria flow cytometer 
(BD) or MACS (Magnetic-activated cell sorting) according to the manufacturer’s 
protocol (Miltenyi Biotec). CD11b (BD Biosciences, 558013) and anti-PE (Miltenyi 
Biotec, 130-048-801) microbeads were used for MACS. For sorting human CD33+ 
myeloid cells, normal human whole blood was obtained from the NIH blood bank in the 
clinical center. Myeloid cells were enriched by Ficoll-PaqueTM (17-1440-02, GE 
Healthcare), then labeled with CD33 microbeads (Miltenyi Biotec, 130-045-501), and 
sorted with MACS (Miltenyi Biotec). 
 
MTT assay 
4T1 cells (3×103) starved under 1% FBS for 24 hours were plated in each well of 
96-well plate and incubated overnight. The cells were then cultured in rmCCL9 
containing media for 2 hours, followed by treatment of low serum (1%), glucose free 
conditions, or doxorubicin (LC Laboratories, gift from Dr. Beverley Mock, NCI. 
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Concentration: 1, 2, 10, 100, 250 nM). MTT assays were performed 24 hours later 
following the protocol below (Sigma, M5655). 
1. Dissolve MTT to 5 μg/μl in diH2O or PBS. This can be stored in 4°C for few 
months. 
2. Add MTT dilute 5 μl per 96-well plate well or 50 μl per 12-well plate well. 
3. Incubate in 37°C for 1-3 hours. 
4. Aspirate off media. 
5. Add DMSO 40 μl per 96-well plate well or 400 μl per12-well plate well. 
6. Read absorbance at 570 nm wave length.  
 
Western blotting  
Protein extraction buffer was diluted with diH2O from 2× lysis buffer (RayBiotech, 
0103004), with addition of proteinase/phosphatase inhibitor (Pierce Biotechnology, 
87785 and 78420) and PMSF (1:1000 dilution from 100mM). Protein concentrations 
were measured using DC Protein Assay Kit (Biorad, 500-0111). Supernatants from 
culture were concentrated using Amicon Centrifuge Filter Unit (Millipore, UFC800324). 
For the TGF-β signaling pathway study, sorted myeloid cells were directly subjected to 
protein extraction (basal state) or starved under 1% FBS for 5 hours before treated with 
TGF-β1 for 1 hour (Cell Signaling, 5231LC, 5 ng/ml). Primary antibodies included TβRII 
(11888), P-p38 (9211), p38 (9212), P-SMAD2 (3101), SMAD2 (3103), PARP (9532), 
caspase 3 (9665), P-AKT (4058), AKT (9272), and AIF (4642). All antibodies above 
were purchased from Cell Signaling and used with a 1:1000 dilution. BCL-2 (Santa Cruz, 
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sc-7382, 1:500 dilution), CCL9 (Peprotech, 250-12, 0.15 μg/ml), and β-actin (Sigma, 
A1978, 1:5,000 dilution) were also used for primary antibody incubation at 4°C 
overnight. Anti-mouse/rabbit secondary antibodies (Bio-Rad, 170-6516 and 170-6515, 
1:3000 dilution) were incubated for 1 hour at room temperature. Whole protein staining 
was performed using MemCode Reversible Protein Stain Kit (Thermo Scientific, 24580).  
 
Cytokine antibody array and ELISA of CCL9 or CCL23 
For the cytokine antibody array, the culture supernatant was collected and processed 
per the manufacturer’s protocol (Raybiotech, AAM-CYT-1000). The expression levels of 
cytokines/chemokines were measured by dot density using the ImageJ software, which 
was then normalized to control dot density and presented as relative expression levels. 
For CCL9 and CCL23 ELISA, the cell culture supernatants or protein extractions from 
cells/mouse organs were collected and processed per the manufacturer’s protocol (R&D, 
DY463 and DY131). 
 
RT-qPCR 
Total RNA was extracted using an RNeasy Mini Kit (Qiagen, 74104) and cDNA 
was synthesized using High-Capacity cDNA Reverse Transcription Kits (Applied 
Biosystem, 4368814). Relative gene expression was determined using SYBR Green PCR 
Master Mix (Applied Biosystem, 4309155). The comparative threshold cycle method was 
used to calculate gene expression and normalized to GAPDH as a reference gene. 
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RT-qPCR primers were as follows. 
CCL9 forward: ATGAAGCCTTTTCATACTGCCCTC 
CCL9 reverse: TTATTGTTTGTAGGTCCGTGGTTG 
CCR1 forward: GTGTTCATCATTGGAGTGGTGG 
CCR1 reverse: GGTTGAACAGGTAGATGCTGGTC 
GAPDH forward: AATGTGTCCGTCGTGGATCTGA 
GAPDH reverse: GATGCCTGCTTCACCACCTTCT 
 
Plasmid constructions 
FUGW plasmid (Gift from Dr. Zheng-Gen Jin, University of Rochester) was used 
for generating CCL9/CCR1 overexpression vectors. CCL9 and CCR1 cDNA were 
ordered from Open Biosystem (EMM1002-99608821 and MMM1013-65208). PCR 
amplified mCCL9 sequence was inserted into BamHI and EcoRI digested FUGW. 
mCCR1 was firstly inserted into BamHI and XhoI digested PCDNA3.1-V5-B for V5 tag. 
mCCR1-V5 was then inserted into FUGW digested with BamHI and BsrGI.  
PLKO.1 plasmid (Gift from Dr. Jing Huang, NCI) was used for CCL9 and CCR1 
knockdown vectors. ShRNA sequences targeting CCL9 or CCR1 were obtained from 
Sigma MISSION RNAi (Table below) and were synthesized by Invitrogen. These oligos 
were aligned and inserted into PLKO.1 vector that was digested with AgeI and EcoRI. 
Sequencing around the inserts was performed to verify the vectors. Restriction enzymes 
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BamHI (R0136), EcoRI (R0101), XhoI (R0146), BsrGI (R0575), and AgeI (R0552) were 
all purchased from New England Biolabs. 
 






























Transfection and electroporation 
Tumor cells (67NR, B16F1) and RAW264.7 cells were transfected with 
LipofectaminLTX per the manufacturer’s protocol (Invitrogen, 15338-500). 
Gr-1+CD11b+ cells sorted from spleens of tumor-bearing wild type, Tgfbr2MyeKO, and 
Tgfbr2Flox mice were transfected using an Amaxa mouse macrophage nuclefector kit per 
the manufacturer’s instructions (Lonza, VPA1009). In brief, 2-3×106 Gr-1+CD11b+ cells 




Graphpad Prism v5.04 was used for graphs and for statistical analyses. Data were 
presented as mean ± standard error (SE). All data were analyzed using the student’s t-test 
for comparison of two groups or one-way ANOVA for three groups or more. Differences 













Chemokine (C-C motif) ligand 9 (CCL9) is a small inflammatory cytokine (12kD). 
It is also known as macrophage inflammatory protein-1 gamma (MIP-1γ), protein-related 
protein-2 (MRP-2), and CCF18.  
Macrophages and myeloid cell lines constitutively express CCL9. This was reported 
in 1995 when CCL9 was firstly discovered using three independent approaches. (1) PCR 
CCL9 cDNA from macrophage cell lines with a degenerate PCR primer set, which was 
designed from the conserved amino acid sequence among C-C chemokines (Youn et al., 
1995). (2) cDNA library subtraction between two cDNA libraries derived from 
EGF-stimulated and non-stimulated EGFR transfected B cell lines Ba/F3 (Hara et al., 
1995). (3) cDNA library screening of RAW264.7 cells (Poltorak et al., 1995). In addition, 
CCL9 is expressed by osteoclasts (Lean et al., 2002) and microglia (Ravindran et al., 
2010). 
CCR1 (CC chemokine receptor type 1) is the only reported CCL9 receptor. CCR1 
is a seven transmembrane protein that interacts with multiple other ligands, including 
CCL3/MIP-1α, CCL5/RANTES (regulated on activation, normal T cell expressed and 
secreted), CCL7, and CCL23 (Neote et al., 1993).  
CCR1 is expressed in both host and cancer cells. Immune cells including monocytes, 
lymphocytes, and dendritic cells express CCR1 (Ogata et al., 1999; Su et al., 1997). 
 29 
Cancer cells including melanoma, breast, and lung cancer cells also express CCR1 (Soria 
et al., 2008; Vallet and Anderson, 2011; Wang et al., 2009). CCR1 knockdown decreases 
tumor cell invasion (Wang et al., 2009; Wu et al., 2007). Furthermore, CCR1 positively 
correlates with the expression levels of stem cell markers SOX2, OCT4, and NANOG 
(Kauts et al., 2013). Overexpression of CCR1 increases the cell viability of mesenchymal 
stem cells (MSCs) (Huang et al., 2010). 
CCL9/CCR1 has been shown to be important for the recruitment of dendritic and 
myeloid progenitors, as well as immature myeloid cells (iMCs) (Kitamura et al., 2007; 
Zhao et al., 2003). In particular, recruited iMCs to the intestinal tumors enhance tumor 
invasion and metastasis (Kitamura et al., 2007). CCL9 knockdown or CCR1 blockade 
significantly decreases tumor progression in vivo by reducing iMC recruitment (Kitamura 
et al., 2010). The CCL9/CCR1 axis is also the major chemokine/receptor axis expressed 
by osteoclasts for the regulation of bone resorption (Lean et al., 2002). Additionally, 
CCL9 functions as a cell survival factor for osteoclasts (Okamatsu et al., 2004). It 
remains unknown whether CCL9 produced by myeloid cells signals through CCR1 on 








CCL9 is significantly produced in the supernatant of Gr-1+CD11b+ and tumor cell 
co-culture 
To address the question whether tumor-educated myeloid cells secrete factors that 
directly promote tumor metastasis at the metastatic site, we co-cultured Gr-1+CD11b+ 
cells with 4T1 mammary tumor cells and performed a cytokine protein array analysis on 
culture supernatants. We sorted Gr-1+CD11b+ cells from spleens of 4T1 tumor-bearing 
mice since they showed a very similar cytokine profile to that of Gr-1+CD11b+ cells 
derived from the lungs of tumor-bearing mice (Fig. 4). Using splenic Gr-1+CD11b+ cells 
was technically more feasible, as enlarged spleens contained a large population of these 
cells in mice bearing 4T1 tumors (Yang et al., 2004).  
Interestingly, we found that CCL9 was significantly induced in the myeloid-tumor 
co-culture supernatant but not in the supernatant of tumor or myeloid cells cultured alone 
(Fig. 5a and b, red boxes). In contrast, other CC family members, including CCL12, 
CCL3, and CCL19, exhibited low expression and did not change significantly in 
co-culture. CCL2, CCL20, and CXCL1 were predominantly produced by tumor cells (Fig. 
5a and b, yellow, cyan, and purple boxes, orderly), in agreement with previous 
publications that tumor cells produce and secrete these cytokines to recruit inflammatory 
monocytes (Qian et al., 2011), immature dendritic cells (Bell et al., 1999), and 
Gr-1+CD11b+ cells (Acharyya et al., 2012). MMP9, a key regulator for tumor vascular 
remodeling (Bergers et al., 2000), was also expressed by these myeloid cells (Fig. 5a and 
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b, blue boxes), consistent with our earlier studies (Yang et al., 2004). This observation of 
CCL9 expression in myeloid-tumor co-culture was confirmed using CCL9 ELISA (Fig. 
6a).  
    To determine whether CCL9 overexpression in the co-culture supernatant was cell 
line specific, we looked at different cell lines, including B16BL6 melanoma in C57BL/6 
background and non-metastatic 67NR mammary gland tumor in BALB/c background. 
CCL9 was also overexpressed in these co-culture supernatants (Fig. 6b and c). We 
therefore focused our efforts on investigating CCL9. 
 
CCL9 is expressed by myeloid cells 
It was important to understand which cell types expressed CCL9 in order to design 
functional studies involving CCL9 knockdown or overexpression. To address this 
question, we separated adherent tumor cells and non-adherent myeloid cells for both 
RT-qPCR and CCL9 ELISA. Both RNA (Fig. 7a) and protein levels (Fig. 7b and c) 
indicated that only myeloid cells expressed CCL9, confirming that tumor cells did not 







   
 
Figure 4. Similarity of cytokine profile between splenic Gr-1+CD11b+ cells and 
those derived from premetastatic lungs of tumor-bearing mice. 
(a) Cytokine protein array of Gr-1+CD11b+ myeloid cells sorted from lungs (left two 
panels) and spleens (right two panels) of tumor-bearing mice 14 days after tumor 
injection. (b) Heat map showing semi-quantitative analysis of (a). Dot density was 
normalized to control dot density and data were presented as relative dot density. Pooled 
samples from 5 mice were used for each group. The myeloid cells were cultured in 




Figure 5. Elevated CCL9 secretion in the co-culture of 4T1 tumor and 
Gr-1+CD11b+ cells. 
(a) Cytokine protein array of supernatants from 24 hours cultured 4T1 tumor, 
Gr-1+CD11b+ myeloid, and myeloid-tumor co-culture. Dots representing CCL9 and 
other CC family members were highlighted with colored boxes. One of two experiments 
performed was presented. (b) Semi-quantitative data of (a). Data presented as dot density. 






Figure 6. CCL9 secretion in other tumor models. 
ELISA or Western blots detecting CCL9 expression in the supernatants of (a) 4T1, (b) 
B16BL6, and (c) 67NR cells, or when co-cultured with splenic Gr-1+CD11b+ cells from 
mice bearing tumors of the same cell line. Supernatants from tumor or Gr-1+CD11b+ 
cells alone served as controls. Whole protein staining on Western blot showed equal 












Figure 7. CCL9 was produced by myeloid cells.  
(a) RT-qPCR showing CCL9 mRNA expression. ELISA showing CCL9 protein 
expression in the supernatant of Gr-1+CD11b+ cells co-cultured with either (b) 4T1 or (c) 














CCL9 is significantly produced in the premetastatic lungs 
We next tested whether CCL9 was up-regulated in the premetastatic lungs, as 
Gr-1+CD11b+ cells and other immature myeloid cells had been reported to be present in 
the lung prior to tumor cell arrival (Hiratsuka et al., 2006; Kaplan et al., 2005; Yan et al., 
2010). The 4T1 and B16F10 models had been reported to have a premetastatic niche 
established after tumor cell inoculation, on day 14 for the 4T1 model (Kowanetz et al., 
2010; Yan et al., 2010) and on day 18 for the B16 model (Kaplan et al., 2005). As 
expected, there was a significantly higher CCL9 expression in the premetastatic lungs 
compared to normal lungs in both 4T1 and B16F10 models (Fig. 8a and b). This elevated 
CCL9 production seen in the premetastatic lungs was not observed in other organs at the 
premetastatic phase of mice bearing 4T1 (Fig. 8d) and B16F10 tumors (Fig. 8e), 
suggesting an organ specificity for the premetastatic niche formation.  
 
Cell-cell contact is not necessary for CCL9 expression 
To ask whether direct contact between tumor cells and Gr-1+CD11b+ cells was 
necessary for CCL9 expression, we cultured Gr-1+CD11b+ cells in tumor-conditioned 
media or in direct contact with tumor cells, and measured CCL9 concentrations in the 
supernatant. Interestingly, Gr-1+CD11b+ cells cultured in tumor-conditioned media 
produced high levels of CCL9 (Fig. 8c). However, CCL9 was produced at a higher level 
in the supernatant where Gr-1+CD11b+ cells were co-cultured with tumor cells (Fig. 8c), 




Only subset Ly6G+CD11b+ cells express CCL9 when co-cultured with tumor cells 
To investigate which cell subset(s) were responsible for CCL9 production, we 
FACS sorted Ly6G+CD11b+ granulocytes, Ly6C+CD11b+ monocytes, and 
F4/80+CD11b+ macrophages (Fig. 9a). These myeloid subsets were then co-cultured 
with tumor cells, and CCL9 production was measured using ELISA. Sorted 
Ly6G+CD11b+ cells produced lower levels of CCL9 than either Ly6C+CD11b+ or 
F4/80+CD11b+ subsets. However, CCL9 production was elevated 20-fold in 
Ly6G+CD11b+ cells, while remaining mostly unchanged in the Ly6C+CD11b+ and 
F4/80+CD11b+ subsets upon co-culture with tumor cells (Fig. 9b). In addition, there 
were significantly more Ly6G+CD11b+ cells in the premetastatic lung (day 14 after 4T1 
tumor injection), while the populations of other cell types were unchanged (Fig. 9c). 
Taking cell number into consideration, CCL9 increase was far greater in the 









Figure 8. CCL9 was significantly up-regulated in the premetastatic lungs. 
ELISA detecting CCL9 expression in the normal and the premetastatic lungs of (a) 4T1 
and (b) B16BL6 tumor-bearing mice. CCL9 expression was also measured in other 
organs at 14 days (d) and 18 days (e) after tumor inoculation. n=3 mice for each group. 
Equal amount of protein extracts were loaded onto the plate and results were presented as 
pg CCL9/μg protein. (c) ELISA assay detecting CCL9 secretion in the supernatant of 
Gr-1+CD11b+ cells when cultured with 4T1 tumor-conditioned media or with tumor 






Figure 9. Myeloid cell subsets in CCL9 production.  
(a) Upper panel: sorting strategy of Ly6G+, Ly6C+, and F4/80+ myeloid cell subsets. 
Lower panel: post-sorting flow cytometry analysis. (b) ELISA showing CCL9 expression 
in subsets upon co-culture with tumor cells. (c) Fold increase in myeloid cell subsets in 
the premetastatic lung (Day 14) and later tumor-bearing stage (Day 21). Fold change in 
cell number was calculated using normal mice as base line. (d) Fold change in CCL9 
expression from myeloid-tumor co-culture supernatant with the consideration of the fold 





CCR1 is expressed by tumor cells 
Since CCR1 is the sole receptor mediating CCL9 signaling (Kitamura et al., 2010; 
Kitamura et al., 2007; Lean et al., 2002; Zhao et al., 2003), we next examined the 
correlation of CCR1 expression in tumor cells with cancer metastasis. We used 4T1 
mammary tumor and B16 melanoma models comprised of cell lines with varying degrees 
of metastatic capability. The CCR1 expression level correlated with the degree of 
malignancy across both cell line panels (Fig. 10a and b). The low metastatic 67NR and 
168FARN cells showed minimum expression of CCR1 mRNA, whereas the highly 
metastatic 4TO7 and 4T1 cells showed approximately 10-fold higher expression (Fig. 
10a). Likewise, the less metastatic B16F1 cells had a lower level of CCR1 mRNA 
expression compared to highly metastatic B16F10 cells (Fig. 10b). Flow cytometry 
analysis revealed approximately 8% of 4T1 cells express CCR1, which was significantly 
higher than that of 67NR, 168FARN, and 4T07 cells (Fig. 10c and d). Interestingly, 
tumor cells from metastatic lung nodules showed higher CCR1 expression than those 










Figure 10. CCR1 expression in tumor cells correlated with metastatic capability.  
RT-qPCR detecting CCR1 expression in (a) mammary gland tumor series and (b) 
melanoma cell line series (c,d) Flow cytometry detecting CCR1+ tumor cells in 
mammary gland tumor series. (e) RT-qPCR detecting CCR1 expression in tumor cell 




Correlation of human CCL23/CCR1 and metastasis free survival  
To establish the clinical significance of our study, we next looked into the 
correlation between CCL23 expression levels and metastasis. CCL23 had been identified 
as the human orthologue for mouse CCL9 (Kitamura et al., 2007; Kowanetz et al., 2010). 
They shared 92-99% sequence identity when examined by the NCBI web tool BLAST 
(Fig. 11a) and clustered together by Treefam analysis (Fig. 11b). They were also 
predicted orthologues by MetaPhOrs online tool (Fig. 11c) and showed similar 
chemoattractant functionality (Kitamura et al., 2007; Patel et al., 1997; Zhao et al., 2003). 
In addition, human CCL23 and mouse CCL9 were two of the four NC6 subfamily 
members in C-C chemokines (Berahovich et al., 2005).  
Using a publicly available dataset (Rotunno et al., 2011), we examined the 
expression level of CCL23 in human peripheral blood mononuclear cells (PBMCs) in a 
cohort of lung cancer patients that contains 48 patients in stage I and II, 30 patients in 
stage III and IV, and 80 healthy individuals. CCL23 was the only up-regulated gene in 
the later tumor stage among all 19 CC cytokines available in this dataset (Fig. 12a). Of 
the remaining cytokines, CCL4 was the only decreased while all other CC cytokines 
showed no change (data not shown). In addition, meta-analysis of 1577 breast cancer 
patients in the GOBO breast cancer database (Ringner et al., 2011) revealed that patients 
with low expression of CCL23/CCR1 had a better survival outcome among 166 PAM50 
HER2+ patients (Fig. 12b), which was not observed in the HER2- patients (data not 
shown). PAM50 (Prediction Analysis of Microarray using 50-gene classifier) is a 50-gene 
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signature that adds further prognostic and predictive information to standard parameters 
for breast cancer patients (Parker et al., 2009). In addition, analysis using the Oncomine 
database (GSE20685) showed a negative correlation of CCL23 and CCR1 expression 
levels with metastatic status three years after breast cancer diagnosis (Fig. 12c, heat map), 
or with a decreased metastasis free survival (Fig. 12c, lower panels). 
 
CCL23 expression in human myeloid cells  
To examine CCL23 induction in human myeloid cells under tumor conditions, we sorted 
human CD33+ myeloid cells from the peripheral blood mononuclear cells (PBMCs) of 
healthy blood donors and co-cultured them with human breast cancer cell lines 
MDA-MB-231/MDA-MD435, lung cancer cell line H460, and melanoma cell lines 
A375S2/SK-MEL-28. Culture supernatants from CD33+ myeloid cells alone, tumor cells 
alone, and the myeloid-tumor co-culture were examined by CCL23 ELISA. Consistent 
with the mouse findings, CCL23 was significantly induced in myeloid-tumor co-culture 
supernatants but not in supernatants from tumor cells or myeloid cells cultured alone (Fig. 
13a), and was mainly produced by myeloid cells (Fig. 13b). This observation was made 
with separation of adherent tumor cells from non-adherent myeloid cells for protein 
extraction and CCL23 ELISA (Fig. 13b). Lastly, MDA-MB-231 conditioned media 
induced CCL23 production (Fig. 13c). Yet, CCL23 was produced at a higher level when 
CD33+ myeloid cells were co-cultured with tumor cells, suggesting that cell-cell 
proximity enhanced CCL9 expression, paralleling our results in mice. Together, our data 
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Figure 11. Human CCL23 was a homologue of mouse CCL9.  
(a) Similarity between mouse CCL9 and human cytokines. (b) Family tree identified by 
the online tool Treefam. (c) Human CCL23 (Phy000875R) was identified as one of the 







Figure 12. CCL23/CCR1 correlated with metastatic status and survival of cancer 
patients. 
(a) CCL23 expression levels in PBMCs of a cohort of lung cancer patients and healthy 
donors, comprising 80 healthy donors, 48 patients in stage I and II, and 30 patients in 
stage III and IV. (b) Kaplan–Meier survival curve of CCL9/CCR1 expression in 166 
PAM50 HER2+ breast cancer patients in GOBO database. (c) Oncomine database 
(GSE20685) showing a correlation of CCL23 or CCR1 expression levels with metastatic 
status 3 years after diagnosis (heat map) or with a decreased overall metastasis free 









Figure 13. Human myeloid cells produced and secreted CCL23. 
(a) CCL23 ELISA of co-culture supernatant. Co-culture of sorted human CD33+ PBMCs 
and indicated human breast, lung, or melanoma cancer cell lines. Culture supernatants 
from CD33+ PBMCs alone, tumor cells alone, or co-culture were also tested. (b) CCL23 
ELISA of protein samples from adherent tumor cells or non-adherent CD33+ PBMCs 
after separation from co-culture. (c) CCL23 ELISA of sorted human CD33+ PBMCs 
cultured in MDA-MB-231 tumor-conditioned media or in co-culture with MDA-MB-231 
cells, with triplicates of samples. CD33+ myeloid cells were sorted and pooled from 





Similarity of cytokine profile between splenic Gr-1+CD11b+ cells and those derived 
from the premetastatic lungs of tumor-bearing mice  
Our study was interested in the tumor-promoting function of Gr-1+CD11b+ cells in 
the premetastatic lung. At this stage, infiltrated Gr-1+CD11b+ cells were induced by 
tumor secreting factors in the microenvironment to execute tumor-promoting function. 
We sorted out both splenic and the premetastatic lung derived Gr-1+CD11b+ cells, and 
they showed a very similar cytokine expression profile when cultured in 
tumor-conditioned media (Fig. 4), indicating that we could use splenic Gr-1+CD11b+ 
cells as a substitute for those from the premetastatic lung. 
This substitution allowed us to overcome the challenge of isolating the small 
Gr-1+CD11b+ cell population from the premetastatic lung. Using 4T1 BALB/c 
mammary gland tumor model as one example, we could only obtain 0.5-1×106 
Gr-1+CD11b+ cells per premetastatic lung, due to small starting cell population and cell 
loss/death during sorting procedures. On the other hand, we could easily harvest 2×108 
Gr-1+CD11b+ cells from spleens of tumor-bearing mice, due to spleen enlargement and 
high proportion of Gr-1+CD11b+ cells. At the meantime, we were aware the possible 
pitfall using splenic cells, and testing key experiments with premetastatic lung derived 




Direct contact is not required, but proximity promotes CCL9 expression   
Our previous study showed that Gr-1+CD11b+ cells promoted lung metastasis by 
building up a proliferative, inflammatory, and tumor-favorable premetastatic lung 
microenvironment (Yan et al., 2010). However, how the secreted chemokines of 
premetastatic tissue differ from normal lung tissue was not clear. In this study, we found 
that Gr-1+CD11b+ cells only expressed and secreted CCL9 when interacting with tumor 
cells. Out of the near 100 cytokines that we tested, only CCL9 was induced in the 
myeloid-tumor co-culture supernatant. The level of CCL9 expression in co-culture was 
about 25-fold higher than in single cultures (Fig. 5), suggesting that CCL9 was likely to 
be one of the most important factors secreted by Gr-1+CD11b+ cells to promote tumor 
cell metastasis.  
Interestingly, tumor-conditioned media stimulated CCL9 expression (Fig. 8). This 
result suggested that primary tumor cells might secrete signaling molecules to promote 
CCL9 expression. These signaling molecules could circulate through the vasculature to 
reach the premetastatic organ before tumor cell arrival. Tumor-conditioned media also 
stimulated human orthologue CCL23 production and secretion by human CD33+ 
myeloid cells, indicating that our mouse study could serve as a model to understand the 
biology of human premetastatic organs, as currently direct testing of the human 




CCL9/CCR1 expression in multiple cancer models  
The CCL9/CCR1 mechanism of promoting cancer metastasis could be applied to 
multiple cancer models. In addition to the 4T1 BALB/c model that we used for our initial 
cytokine screening (Fig. 5), we examined other tumor cell lines of different mouse 
backgrounds. These included B16BL6 in C57BL/6 background and 67NR in BALB/c 
background (Fig. 6). More importantly, we found a negative correlation of metastatic 
status and patient survival with CCL23 expression in PBMCs, which included a high 
number of immature myeloid cells when under tumor conditions (Fig. 12). The same 
correlation was shown in the examinations of CCL9/CCR1 expression in the primary 
tumors (Fig. 12).  
 
Different CCL9 expression in myeloid cells when cultured alone may be due to 
different subset compositions 
Gr-1+CD11b+ cells include Ly6G+, Ly6C+, and F4/80 three subsets. We observed 
that only Ly6G+ cells significantly increased CCL9 production when stimulated by 
tumor cells. The other two subsets, although producing CCL9 without tumor cell 
stimulation, did not further increase the CCL9 secretion (Fig. 9). Since Ly6G+ was the 
major cell subset in the premetastatic lung, the effect of Ly6G+ cells in terms of CCL9 
expression was far greater than the Ly6C+ or F4/80+ subsets (Fig. 9). As a result, Ly6G+ 
should be the targeted cell type for the future studies of CCL9 neutralization or 
knockdown. 
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Our initial cytokine protein screen in the 4T1 tumor model showed that CCL9 was 
not secreted by Gr-1+CD11b+ cells when cultured alone (Fig. 5). We further confirmed 
this finding by using both ELISA and Western blots (Fig. 6). However, Gr-1+CD11b+ 
cells secreted some CCL9 when sorted from spleens of B16BL6 tumor-bearing C57BL/6 
mice and cultured alone (Fig. 6). This was likely due to the differences in subset 
compositions between different animal backgrounds. As shown in Fig. 9 of single 
cultures, both Ly6C+ and F4/80 subsets expressed CCL9, whereas Ly6G+ exhibited 
almost no CCL9 expression.  
Gr-1+CD11b+ cells in 4T1 and 67NR models were from BALB/c background, and 
Gr-1+CD11b+ cells in B16BL6 models were from C57BL/6 background. Compared to 
BALB/c, C57BL/6 mice were known to polarize in type 1 immune responses with higher 
resistance to diseases (Chaudhri et al., 2004). Thus, there was a higher percentage of 
F4/80 myeloid cells in mice of the C57BL/6 background, which exhibit elevated CCL9 
expression (Fig. 9).  
 
CCL9 is expressed mostly in myeloid but not tumor cells, different from some previous 
publications 
Our data were in agreement with reports that CCL9 was secreted in macrophages 
and myeloid cell lines including mouse 32D neutrophil, P388D1/RAW264.7 macrophage 
cell lines (Hara et al., 1995; Okamatsu et al., 2004). These data were different from two 
previous reports in which CCL9 was expressed and secreted by tumor cells (Kitamura et 
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al., 2007; Owens et al., 2012). However, neither paper had a clean system where tumor 
cells were exclusively separated. One paper performed IHC staining on colon tumor 
tissue, as well as RT-qPCR on laser captured tumor tissue (Kitamura et al., 2007). The 
other paper cultured primary mammary tumor and detected CCL9 in the culture 
supernatant (Owen-Schaub et al., 1998). Both papers looked at CCL9 expression in the 
whole tumor tissue, which was known to have a high residency of myeloid cells and other 

















THE PARACRINE AND AUTOCRINE EFFECT OF CCL9/CCR1: 
PROMOTING THE SURVIVAL OF TUMOR AND GR-1+CD11B+ CELLS 
 
Introduction 
Tumor cell survival is the rate-limiting step in cancer metastasis. Metastasis is an 
inefficient process, as the majority of cancer cells die in the peripheral blood or distant 
hostile organs before they reach their full metastatic potential (Mehlen and Puisieux, 
2006).  
The host effect is important in promoting tumor cell survival. Evidence from recent 
years strongly suggests that host cells in the microenvironment, especially myeloid cells 
in the secondary organ, play a critical role in enhancing tumor cell survival and 
metastasis (Kang and Pantel, 2013). For example, macrophages expressing α4 integrin 
that binds to vascular cell adhesion molecule-1 (VCAM-1) expressed on tumor cells 
(Chen et al., 2011); Gr-1+CD11b+ cells expressing S100A8/9 that promote tumor cell 
survival (Acharyya et al., 2012). We have reported that Gr-1+CD11b+ cells are 
significantly recruited in the premetastatic lung and to modulate the microenvironment 
through cytokine/chemokine expressions (Yan et al., 2010). However, it is unknown 
whether these myeloid cells can directly support tumor cell survival in the premetastatic 
organs and what the molecular mechanisms may be.  
Whether CCL9/CCR1 promotes tumor metastasis through enhanced tumor cell 
survival is unknown. CCL9 is a known cell survival factor for osteoclasts. CCL9 
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neutralization significantly decreases cell survival stimulated by RANKL (receptor 
activator of NF-κB ligand) in vitro compared to the control treated group (Okamatsu et 
al., 2004). Additionally, CCR1 promotes MSC survival as overexpression of CCR1 
significantly reduces TUNEL+ cells that are induced by serum depletion (Huang et al., 
2010). CCL9/CCR1 is reported to promote metastasis through recruitment of CCR1+ 
myeloid cell to assist tumor cell invasion (Kitamura et al., 2007). CCL9 knockdown or 
CCR1 blockade significantly decreases tumor progression in vivo by reducing the 
accumulation of iMCs at the tumor invasive front (Kitamura et al., 2010). It remains 
unknown whether CCL9 directly signals through CCR1 and functions as a tumor cell 
survival factor. 
In Chapter III, we discovered a significant increase of CCL9 production and 
secretion by the Gr-1+CD11b+ cells when co-cultured with tumor cells, and in the 
premetastatic lung compared to the normal lung. In this chapter, we will address the 
















CCL9/CCR1 signaling promotes tumor metastasis   
Immature myeloid cells had been shown to promote cancer metastasis (Kang and 
Pantel, 2013; Psaila and Lyden, 2009). Consistent with this, luciferase labeled 4T1 
(4T1-luc) mammary tumor cells, when co-injected with Gr-1+CD11b+ cells, showed 
increased metastasis. This result was shown by luciferase image quantification (Fig. 14a 
and b). 67NR, a relatively non-metastatic cell line derived from the same mammary 
tumor as 4T1, showed a 3-fold increase in metastasis when co-injected with 
Gr-1+CD11b+ cells by tail vein injection (Fig. 14c).  
To overcome the technical difficulties of gene modification in primary 
Gr-1+CD11b+ cells, we firstly explored whether RAW264.7 macrophage or 32DCl3 
neutrophil cell lines could be used for stable CCL9 knockdown. Both cell lines constantly 
expressed CCL9 (Hara et al., 1995; Okamatsu et al., 2004) and they might produce 
cytokines similar to Gr-1+CD11b+ cells under tumor conditions. When cultured in 4T1 
tumor-conditioned media, RAW264.7 macrophages showed a similar cytokine profile to 
primary Gr-1+CD11b+ cells, especially in their high level expression of CCL9, which 
was not seen in the 32Dcl3 neutrophil cell line (Fig. 15a and b, blue boxes). In addition, 
RAW264.7 cells showed a metastasis-promoting effect similar to Gr-1+CD11b+ cells 
when co-injected with tumor cells through the tail vein (Fig. 15c). We next decided to 
knockdown CCL9 in RAW264.7 cells to study the function of myeloid CCL9 in tumor 
metastasis. 
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To determine whether CCL9 is a critical mediator in the myeloid promotion of 
cancer metastasis, we transiently knocked down CCL9 in Gr-1+CD11b+ cells. We were 
able to achieve about 40% knockdown in primary Gr-1+CD11b+ cells (Fig. 16a). 
CCL9-deficient Gr-1+CD11b+ cells significantly decreased lung metastasis compared to 
the control group (Fig. 16b). This metastasis difference was not due to altered primary 
tumor sizes (Fig. 16c). Next, we stably knocked down CCL9 in RAW264.7 cells. We 
utilized two shRNAs that represented 50% and 90% knockdown (Fig. 16d). Again, 67NR 
tumor cells showed a decreased lung metastasis when co-injected with CCL9-deficient 
RAW264.7 cells compared to those co-injected with the control RAW264.7 cells (Fig. 
15e and f). The degree of metastasis inhibition correlated with the level of CCL9 
knockdown (Fig. 15d to f), indicating that the metastatic change was truly due to CCL9 
expression levels rather than an off-target effect. 
These results further demonstrated that RAW264.7 cells were a good substitute for 
primary Gr-1+CD11b+ cells since we could achieve a more efficient and varied 
knockdown in RAW264.7 cells (Fig. 16d). More importantly, RAW264.7 cells and 
Gr-1+CD11b+ cells resulted in a very similar level of CCL9-mediated tumor promotion 
(Fig, 15c, 16 b, e, and f). Together, our data suggested a unique function of myeloid 





Figure 14. Gr-1+CD11b+ cells promoted tumor metastasis. 
(a) Luciferase live imaging 7 days after tail vein co-injection of 5×105 4T1-luc with 
1×106 Gr-1+CD11b+ cells. Mice n=5 for each group. (b) Quantitative data of (a). (c) 
Number of lung metastasis resulting from co-injection of 5×105 67NR tumor cells with 











Figure 15. Similar cytokine profile of splenic Gr-1+CD11b+ cells, RAW264.7 cells, 
and 32DCl3 cells. 
(a) Cytokine protein array of primary Gr-1+CD11b+ cells (sorted from spleens of 
tumor-bearing mice), RAW264.7 macrophage cell line, and 32Dcl3 neutrophil cell line, 
after co-culture with 4T1 tumor-conditioned media overnight. Blue boxes on blots 
indicate CCL9 expression. (b) Heat map based on semi-quantitative data from (a). Dot 
density was normalized to control dots. Blue box indicated CCL9 expression. (c) Lung 
metastasis of 4T1 cells co-injected with Gr-1+CD11b+ or RAW246.7 cells. n=9-10 mice 




Figure 16. Decreased lung metastasis upon CCL9 knockdown in RAW264.7 or 
Gr-1+CD11b+ cells. 
(a) CCL9 expression after knockdown in RAW264.7 cells. (b) Lung metastasis of 67NR 
tumor cells co-injected with RAW264.7 cells deficient in CCL9 expression. (c) Primary 
tumor size when 67NR cells were co-injected with CCL9-deficient Gr-1+CD11b+ cells 
into mammary fat pad. (d) CCL9 expression after knockdown in primary Gr-1+CD11b+ 
cells. (e) Lung metastasis of 67NR tumor cells co-injected with CCL9-deficient 
Gr-1+CD11b+ cells. (f) Representative pictures of (e). For both (a) and (d), CCL9 
expression was detected by ELISA. Mice received tail vein (b)(e)(f) or mammary fat pad 
(c) co-injection of 5×105 67NR and 2×105 RAW264.7 cells or 1.5×106 Gr-1+CD11b+ 
cells. Mice were euthanized 4 weeks after cell injection. Mice n=8-9 for each group. 




CCR1 mediates CCL9 signaling and promotes tumor metastasis 
CCR1 was reported as the sole receptor mediating CCL9 signaling (Kitamura et al., 
2010; Kitamura et al., 2007; Lean et al., 2002; Zhao et al., 2003). As described in Chapter 
III, we found that CCR1 was expressed by tumor cells and the expression level correlated 
with cancer metastasis (Fig. 10). To examine whether CCR1 was important for lung 
metastasis, we sorted CCR1+ tumor cells and tried to expand them in vitro. However, the 
majority of CCR1+ cells lost CCR1 expression during culture. We then overexpressed 
CCR1 in low metastatic 67NR and B16F1 cells (Fig. 17a and c). Mice bearing 
67NR-CCR1 or B16F1- CCR1 tumor cells showed increased lung metastasis compared 
to 67NR-control or B16F1-control cells (Fig. 17b and d). Highly metastatic cell lines 4T1 
or B16F10 served as positive controls (Fig. 17) 
To further investigate whether CCL9 signaled through CCR1 to promote cancer 
metastasis, we co-injected CCL9-deficient RAW264.7 cells with 67NR-CCR1 cells. 
Consistently, CCL9 knockdown in RAW264.7 cells decreased tumor metastasis and 
CCR1 overexpression in tumor cells increased tumor metastasis when co-injected with 
RAW264.7 cells retained a high level of CCL9 expression (Fig. 18). Importantly, CCR1 
overexpression in 67NR cells did not rescue the metastasis deficiency in the context of 
myeloid-specific CCL9 knockdown. This result indicated that CCL9, but not other CC 
cytokine family members, was likely the major cytokine signaling through the CCR1 
receptor to promote metastasis. This finding was consistent with our earlier observation 




Figure 17. Overexpression of CCR1 increased lung metastasis. 
(a) qRT-PCR showing CCR1 overexpression in 67NR cells. (b) Lung metastasis of 
67NR cells with CCR1 overexpression (67NR-CCR1) and control (67NR-control). Mice 
received tail vein injection of 67NR-CCR1, 67NR-control, or 4T1 cells; the lungs were 
harvested 21 days later. Left panel: representative H&E sections of mouse lungs; Right 
panel: lung weights, n=7-8 mice for each group. (c) qRT-PCR showed CCR1 
overexpression in B16F1 cells. (d) Number of lung metastasis in mice that received tail 
vein injection of B16F1-CCR1, B16F1-vec, or B16F10 cells. Lungs were collected 21 
days after tail vein injection and subjected to whole lung mounting procedure. n=8-9 













Figure 18. CCL9/CCR1 promoted tumor metastasis. 
(a) Lung weights and (b) representative pictures of tumor-bearing mice that received the 
co-injection of 67NR-CCR1 cells or its control with RAW264.7 cells with CCL9 















CCL9 promotes tumor cell survival  
When 4T1 cells were introduced into the venous circulation of mice, the majority of 
4T1 tumor cells died within 24 hours after arrest at the secondary site (Fig. 19). To 
investigate the effect of myeloid-derived CCL9 on tumor cell survival in the 
premetastatic lung, we utilized fluorescence imaging of single cell video microscopy 
(SCVM) and pulmonary metastasis assay (PUMA). SCVM detected single tumor cell 
survival in vivo, which allowed us to examine the effect of myeloid CCL9 on tumor cell 
survival. Lungs subjected to SCVM were further analyzed using the TUNEL assay to 
detect apoptotic tumor cells. PUMA evaluated tumor cell colonization ex vivo in the 
cultured lung slice 7-14 days after tail vein co-injection of myeloid and tumor cells 
(Mendoza et al., 2010).  
We used 67NR-GFP or B16F1-GFP cells in these assays, as they are more 
vulnerable to the effects of CCL9 knockdown in myeloid cells compared to highly 
metastatic 4T1-GFP or B16F10-GFP cells. Using SCVM and TUNEL assays, we found 
that CCL9 knockdown in RAW264.7 cells decreased the survival and increased apoptosis 
of 67NR-GFP cells (Fig. 20a) and B16F1-GFP tumor cells (Fig. 20c). CCL9 knockdown 
in RAW264.7 cells also decreased metastatic colony formation of 67NR-CCR1 (Fig. 21a) 
and B16F1 cells (Fig. 21c), as demonstrated by PUMA. These results were further 
validated through CCL9 knockdown in primary Gr-1+CD11b+ myeloid cell, which 
increased tumor cell apoptosis (Fig. 20b) and decreased tumor cell survival and 




Figure 19. The majority of tumor cells died within 24 hours after tumor inoculation. 
5×105 4T1-GFP cells were tail vein injected into BALB/c mice. Lungs were taken out 
after indicated hours for confocal imaging. (a) Representative confocal images at each 
indicated time point. (b) Quantitative data showed as fluorescence signal per field. Each 
time point result was the average of 6 random fields under 20× magnification. 3 mice per 











Figure 20. CCL9 knockdown in myeloid cells decreased tumor cell survival and 
increased tumor cell apoptosis in vivo. 
SCVM for tumor cell survival (left y-axis) and TUNEL assay for tumor cell apoptosis 
(right y-axis). (a) GFP labeled 67NR cells were co-injected with 2×105 RAW264.7 cells 
with or without CCL9 knockdown. Upper panel: quantitative data. Lower panel: 
representative SCVM pictures 6 hours after injection. (b) GFP labeled 67NR cells were 
co-injected with 1.5×106 Gr-1+CD11b+ cells with or without CCL9 knockdown. (c) GFP 
labeled B16F1 cells were co-injected with 2×105 RAW264.7 cells with or without CCL9 
knockdown. Ten fields for each mouse lung were examined. Fluorescent signals at 6 
hours were normalized to 1 hour (baseline) signals. n=3-4 mice per group. Fixed lung 
tissues were then stained with GFP to label the tumor cells and TUNEL assay to identify 












Figure 21. CCL9 knockdown in myeloid cells decreased tumor cell colonization. 
PUMA for tumor cell survival and metastasis. (a) GFP labeled 67NR cells were 
co-injected with 2×105 RAW264.7 cells with or without CCL9 knockdown. Upper panel: 
quantitative data. Lower panel: representative PUMA pictures 7 days after lung section 
culture. (b) GFP labeled 67NR cells were co-injected with 1.5×106 Gr-1+CD11b+ cells 
with or without CCL9 knockdown. (c) GFP labeled B16F1 cells were co-injected with 
2×105 RAW264.7 cells with or without CCL9 knockdown. Signals obtained on day 7 
were normalized to those from day 0 (baseline) and presented as pulmonary metastasis 
index. Three mice each group, 3-4 lung pieces each mouse. * P<0.05, ** P<0.01, 







CCL9 does not affect tumor cell extravasation 
Tumor cell extravasation had been thought to be an important step prior to tumor cell 
survival in the distant metastatic organs. Tumor cells unable to extravasate died in blood 
vessels, while those that successfully extravasated were more likely to survive (Valiente 
et al., 2014). Thus, we aimed to understand whether increased tumor cell survival was 
due to a direct CCL9 effect or through an increased extravasation. To answer this 
question, we injected 67NR-GFP cells together with fluorescent dextran through the tail 
vein. We took confocal images of lungs 6 hours after injection and analyzed the data by 
counting green fluorescent 67NR-GFP tumor cells against a red vascular map (Dextran 
labeled) (Fig. 22b). We found that Gr-1+CD11b+ cells promoted tumor cell extravasation, 
which was consistent with a previous publication (Yang et al., 2008a). However, 
knockdown of CCL9 in Gr-1+CD11b+ cells did not affect tumor cell extravasation 




Figure 22. CCL9 did not affect tumor cell extravasation.  
Confocal images were taken with indicated cell injection through the tail vein. Blood 
vessels were labeled with dextran. (a) Percentage of extravasated tumor cells over total 










Molecular mechanisms by which CCL9 promotes tumor cell survival 
To determine the effect of CCL9 on tumor cell survival in vitro, we continued to use 
the low metastatic 67NR mammary tumor cells and B16F1 melanoma cells that were 
more sensitive to apoptosis induction upon serum starvation and glucose free culture 
conditions. Recombinant mouse CCL9 (rmCCL9) decreased the number of 
7AAD+/AnnexinV+ 67NR and B16F1 cells, while CCL9 neutralization had the opposite 
effect (Fig. 23a and b). rmCCL9 also increased the survival of 67NR cells when cultured 
in glucose free conditions (Fig. 23c). Furthermore, 4T1 cells treated with doxorubicin 
showed an increased survival upon rmCCL9 treatment (Fig. 23d and e). 67NR cells were 
not used as they were mostly killed by doxorubicin treatment. 
We next addressed the molecular mechanisms underlying CCL9 promotion of 
tumor cell survival. We firstly looked into AKT pathway, as this was reported to promote 
lung cancer cell survival upon CCL5/CCR1 activation (Huang et al., 2009). We found 
that rmCCL9 increased phosphorylated-AKT (p-AKT), whereas CCL9 neutralizing 
antibody (NeuAB) decreased p-AKT expression (Fig. 24a). Secondly, we looked into the 
caspase-dependent apoptosis pathway (Fig. 24c). The apoptosis was likely independent of 
the caspase cascade as there was no change in cleaved caspase 3 when treated with 
rmCCL9 or CCL9 NeuAB (Fig. 24a). We then looked into an important non-canonical, 
poly (ADP-ribose) polymerase (PARP)-dependent apoptosis pathway (Schreiber et al., 
2006) (Fig. 24d). rmCCL9 decreased PARP expression in 67NR cells whereas CCL9 
NeuAB elevated its expression in 67NR cells that were cultured in myeloid-tumor 
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co-culture supernatant (Fig. 24a). Immunofluorescence (IF) staining of PAR, the substrate 
of PARP, showed that rmCCL9 decreased PAR, whereas CCL9 NeuAB elevated PAR in 
B16F1 cells cultured in myeloid-tumor co-culture supernatant, supporting a role of the 
PARP in CCL9 promotion of tumor cell survival (Fig. 24b). BCL-2, a molecular inhibitor 
of PARP pathway, was also elevated when rmCCL9 was applied and decreased when 
CCL9 NeuAB was added (Fig. 24a). Together, these data indicated that CCL9 activates 
the AKT cell survival pathway and inhibits the PARP-dependent apoptosis pathway (Fig. 
24e).  
 
The autocrine effects of CCL9/CCR1 in Gr-1+CD11b+ cells 
 
CCL9 had been reported to inhibit apoptosis in osteoclasts, one of the myeloid cell 
types (Okamatsu, 2004). We therefore asked whether CCL9 had an effect on 
Gr-1+CD11b+ cell survival. As expected, CCL9 neutralization increased apoptosis of 
Gr-1+CD11b+ cells cultured in tumor-conditioned media (Fig. 25a). In addition, 
knockdown of CCR1 in RAW264.7 cells decreased their CCL9 production (Fig. 25b), 





Figure 23. CCL9 promoted tumor cell survival in vitro.  
Flow cytometry analysis of (a) 67NR and (b) B16F1 cells stained with Annexin V and 
7AAD after co-cultured in the indicated conditions. MTT assay showing tumor cell 
survival when treated with rmCCL9. (c) 67NR cells under low serum and glucose free 
culture conditions, as well as (d) (e) 4T1 cells with anti-cancer drug doxorubicine. 
rmCCL9 was added to 4T1 cells before overnight treatment of doxorubicine. The 
experiment were repeated 2-3 times, data shown was a representative performed with 











Figure 24. Molecular mechanisms of CCL9-mediated tumor cell survival.  
(a) Western blots of P-AKT, AKT, BCL-2, PARP, caspase 3, cleaved caspase 3, as well as 
β-actin. 67NR cells were firstly starved under low serum (1%) for 24 hours and then 
treated as indicated. (b) PAR and nuclei fluorescence staining (PAR in green, with nuclei 
in blue) of serum starved B16F1 cells treated with rmCCL9 or CCL9 NeuAB when 
cultured in myeloid-tumor co-culture supernatant. (c) Caspase dependent apoptosis 
pathway. Figure adapted from: Nat Rev Cancer. 2002 Dec;2(12):927-37. (d) 
PARP-dependent apoptosis pathway. Figure adapted from: Sci Signal. 2011 Apr 
5;4(167):ra20. doi: 10.1126/scisignal.2000902. Molecules labeled with red boxes are the 
ones altered when treated with rmCCL9 or CCL9 NeuAB. (e) Schematic pathways for 
tumor cell survival and apoptosis regulated by CCL9. Abbreviation: rmCCL9: 
recombinant mouse CCL9; CoSN: myeloid-tumor co-culture supernatant; CCL9 NeuAB: 









Figure 25. Autocrine effect of CCL9/CCR1 on Gr-1+CD11b+ cells. 
(a) Flow cytometry analysis of AnnexinV and 7AAD of stained Gr-1+CD11b+ cells 
cultured in myeloid-tumor co-culture supernatant and treated with CCL9 neutralizing 
antibody. Three mice were used for each group. (b) CCL9 expression (ELISA, left Y-axis) 
and relative expression of CCR1 (RT-qPCR, right Y-axis) upon CCR1 knockdown in 


























RAW264.7 cells as a substitute for Gr-1+CD11b+ cells 
 
RAW264.7 cells showed a very similar cytokine profile when compared with 
Gr-1+CD11b+ cells, especially in the CCL9 expression levels (Fig. 15). With only a 
small amount of variations in other cytokine expressions, RAW264.7 cells provided an 
effective model for us to investigate CCL9 function using the CCL9 knockdown 
approach. In addition, RAW264.7 cells had a very similar tumor-promoting function as 
Gr-1+CD11b+ cells (Fig. 15) and exhibited decreased metastasis with CCL9 knockdown 
(Fig. 16). In the efforts to understand how CCL9 promotes metastasis, we performed 
SCVM, TUNEL, and PUMA to test tumor cell survival and colonization in both 
RAW264.7 and Gr-1+CD11b+ cells with similar results. 
The biggest advantage of using RAW264.7 over Gr-1+CD11b+ cells was that we 
achieved a much higher degree of knockdown in RAW264.7 cells. RAW264.7 cells of 
CCL9 knockdown had a puromycin resistant gene, which was co-expressed with shRNAs. 
As a result, the CCL9 expression level was stable in these cells as they were under drug 
selection in culture. The different degrees of CCL9 expression helped us to understand 
whether decreased metastasis was due to CCL9 expression level or an off-target effect.  
There was a possibility that our results obtained from RAW264.7 cells are different 
from Gr-1+CD11b+ cells. To address this in future, using conditional CCL9 KO mice 
would be the most ideal choice, but myeloid specific CCL9 knockout mice were not 
readily available. Although the total KO mice were available from the Knockout Mouse 
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Project (KOMP), it required cryorecovery from frozen embryos, which would take at 
least nine months to complete. In addition, not only the cost was rather high, but also we 
would need to cross breed for at least 5 generations to match our study models in 
BALB/c and C57BL/6 backgrounds. Therefore, considering the cost and time constraints, 
we were unable to utilize these mouse models in my studies. 
 
Using lower metastatic 67NR and B16F1 cells to study the tumor-promoting function 
of CCL9 and CCR1 
We chose to use low metastatic 67NR and B16F1 cells when we tested whether 
CCL9 could increase metastasis and survival, because the basal level of metastasis in 4T1 
and B16F10 cells was already high (Fig. 17). These experiments included all the 
co-injections (Fig. 16, 20 to 22) and co-cultures (Fig. 23 and 24) of tumor and 
Gr-1+CD11b+ cells with or without CCL9 knockdown. In addition, in the experiments 
utilizing overexpression of CCR1 in tumor cells, we used 67NR/B16F1 since 
4T1/B16F10 cells had intrinsically high level of CCR1 (Fig. 17). 
 
CCL9 neutralization or knockdown in primary myeloid cells as an option for 
metastasis treatment 
We had explored extensively the possibility of treating mice with CCL9 NueAB. 
Due to the prohibitive cost, we were unable to immediately start this experiment, and so 
will be one of the future directions to explore.  
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However, modification of protein expression in primary cells was achievable. 
CCL9 knockdown from Gr-1+CD11b+ cells clearly decreased tumor metastasis (Fig. 16). 
It would be very interesting to further explore the clinical applications of this result. 
Potential experiments could include introducing CCL9-deficient Gr-1+CD11b+ cells to 
lethally irradiated tumor-bearing mice. We have already successfully knocked down 
CCL9 in Gr-1+CD11b+ cells by electroporation. Our lab also has extensive experience in 
bone marrow transplantation of irradiated mice, in which majority of white blood cells 
are dysfunctional. We can use this approach to test whether CCL9-deficient 
Gr-1+CD11b+ cells block the metastasis promoting effect as a promising pre-clinical 
study. We could also treat tumor-bearing mice with CCL9 shRNA driven by the CD11b 
promoter in vivo. Our lab have developed the system where TGF-β shRNA that under the 
myeloid cell promoter CD11b were tail vein injected into tumor-bearing mice for three 
weeks. TGF-β shRNA reprogrammed these cells from type 2 into type 1 that displays 
tumor-inhibiting function to reduce metastasis. CCL9 that identified in this study is a new 
promising target and specific knockdown in myeloid cells in vivo may inhibit metastasis 
as an indication for clinical treatment. 
 
CCL9/CCR1 promotes metastasis by enhancing tumor cell survival 
To our best knowledge, we first time identified CCL9 as a key player in promoting 
cell survival in the premetastatic lung, for both tumor and Gr-1+CD11b cells (Fig. 20, 23, 
and 25). In a previous publication, the authors showed that iMCs formed a permissive 
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premetastatic niche for the incoming tumor cells (Kaplan et al., 2005). However, a 
co-localization of tumor and Gr-1+CD11b+ cells in the premetastatic lung was not 
observed in our tumor models. CCL9 was significantly induced in the premetastatic lung 
microenvironment and enhanced tumor cell survival without a spatial restriction. In other 
words, overlapping of tumor and Gr-1+CD11b+ cells was unnecessary for CCL9 to 
function as a metastasis promoter.  
Our results add a more complete understanding of CCL9/CCR1 function. A 
previous publication demonstrates CCL9/CCR1 as cell attractant molecules. CCL9 
recruits CCR1+ iMCs, which secrete MMP2 and MMP9 to promote tumor cell invasion 
at the tumor invasive front (Kitamura et al., 2007). Their study and ours indicate that 
CCL9/CCR1 is critical for both tumor cell invasion and survival. Thus, CCL9/CCR1 may 
serve as a more promising therapeutic target. 
 
Gr-1+CD11b+ cells are metastasis-promoting 
Our study showed a tumor-promoting function of Gr-1+CD11b+ cells. This was 
consistent with the metastasis-promoting effect of Gr-1+ inflammatory monocytes (Qian 
et al., 2011), immature myeloid cells (Hiratsuka et al., 2006), and VEGFR1+ myeloid 
progenitor cells (Kaplan et al., 2005). 
Our result was different from a recent publication, which indicated that 
Ly6G+CD11b+ cells exhibit an anti-tumor function (Granot et al., 2011). These 
differences most likely reflected the context-dependent functionality of myeloid cells, 
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such as time and spatial factors in mouse models. In their study, the authors showed that 
neutralization of Ly6G+CD11b+ cells promoted metastasis. Such neutralization was only 
successful before, but not after, the premtastatic stage (day 14 after tumor inoculation). 
This might be due to the fact that Ly6G+ cells only become tumor-promoting around day 
14 when primary tumor secreted factors circulate to and function in the secondary organ. 
In support of this idea, we found that CCL9 only became significantly upregulated at the 
premetastatic lung stage (Fig. 8) 
 
The autocrine effect of CCL9/CCR1 
CCL9 was expressed by Gr-1+CD11b+ cells, which also expressed high level of 
CCL9 receptor CCR1 (Fig. 25). In one previous publication, CCL9/CCR1 was reported 
to recruit myeloid cells into primary tumor tissue (Kitamura et al., 2007). Here we found 
a novel function of this cytokine/receptor axis to promote the cell survival of 
Gr-1+CD11b+ cells. Gr-1+CD11b+ cells are an important component in supporting 
incoming metastatic tumor cells, thus the survival of those cells is critical.  
CCL9/CCR1 inducing CCL9 secretion is an important mechanism to further 
amplify CCL9 signal to promote the survival of both cell types. Neutralization or 
knockdown of CCL9 may have a compounded effect on both tumor and Gr-1+CD11b+ 






CCL9 IS A CRITICAL EFFECTOR OF MYELOID TGF-β SIGNALING THAT 
PROMOTES METASTASIS 
Introduction 
TGF-β displays activity as both a metastasis promoter and a suppressor. Large 
amounts of evidence suggest that TGF-β signaling functions as a metastasis suppressor in 
epithelial cells (Forrester et al., 2005; Kitamura et al., 2007), fibroblasts (Hembruff et al., 
2010), and T cells (Kim et al., 2006), as the deletion of TGF-β pathway molecules in 
these cell types promotes tumor progression. Distinct from the cell types discussed above, 
myeloid specific TGF-β functions to promote metastasis. Our lab has previously 
discovered a significantly decreased metastasis when TGF-β receptor II (TβRII) is 
deleted specifically in the myeloid cell population (Fig. 26a). This is obtained by using 
mice with a targeted deletion of Tgfbr2 in myeloid cells (Tgfbr2MyeKO). These knockout 
mice are generated by cross breeding floxed Tgfbr2 (Tgfbr2flox/flox) with LysM-Cre 
transgenic mice, as LysM is a myeloid specific promoter (Pang et al., 2013).  
Cytokines are the key effectors of TGF-β signaling pathway. TGF-β promotes the 
expression of chemokines that attract inflammatory cells into the tumor 
microenvironment (Bierie et al., 2009; Ijichi et al., 2011; Pickup et al., 2013; Yang et al., 
2008a). For example, deletion of TGF-β in mammary gland epithelial cells increases 
CXCL5 and CXCL12, also known as stromal derived factor 1, (SDF-1). These cytokines 
attract CXCR2+ and CXCR4+ Gr-1+CD11b+ cells to promote tumor invasion (Yang et 
al., 2008a). Our own study further supports this idea, a decrease in type 2 cytokines and 
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increase in type 1 cytokine IFN-γ was found in TGF-β deficient Gr-1+CD11b+ cells 
(Pang et al., 2013).  
Interestingly, we have observed decreased CCL9 expression in TGF-β deficient 
Gr-1+CD11b+ cells along with significantly decreased tumor metastasis in Tgfbr2MyeKO 
mice (Fig. 26 a and b). As shown in Chapter II, CCL9 promotes tumor cell survival and 
metastasis. This leads us to hypothesize that CCL9 may be an important regulator in 
myeloid TGF-β pathway to promote metastasis though supporting cell survival. In this 
chapter, we will test this possibility by overexpressing CCL9 in TGF-β deficient 
Gr-1+CD11b+ cells, then analyzing metastatic changes.  
TGF-β signaling pathways include the canonical SMAD-dependent pathway and 
non-canonical SMAD-independent pathways (Bierie and Moses, 2006). Myeloid TGF-β 
is tumor-promoting, as opposed to tumor-suppressing in other reported cell types. This 
unique functionality in myeloid cells may be due to a different downstream TGF-β 
pathway from other cell types. In this chapter, we will also look into which downstream 









Myeloid TGF-β promotes CCL9 expression 
In our recent study on the function of myeloid TGF-β signaling in metastasis, we 
found a significantly decreased tumor metastasis in Tgfbr2MyeKO mice when compared to 
Tgfbr2Flox mice (Fig. 26a). This phenotype was also observed in various tumor models 
(Pang et al., 2013). TβRII-deficient Gr-1+CD11b+ cells displayed a significantly 
decreased CCL9 expression in a cytokine protein array (Fig. 26b). We further confirmed 
these results with ELISA using multiple TβRII-deficient or control tumor-bearing mice 
(Fig. 26c). In addition, TGF-β neutralizing antibody 1D11 decreased CCL9 expression in 
vitro, as compared to the 13C4 control antibody (Fig. 26d). 
 
CCL9 is a critical effector of the myeloid TGF-β signaling that promotes metastasis 
Unlike wild type Gr-1+CD11b+ cells, TβRII-deficient Gr-1+CD11b+ cells failed to 
support tumor cell survival in vivo when examined by SCVM (Fig. 27a). Instead, these 
cells restored tumor cell apoptosis to a level similar to that of the tumor cells alone group 
(Fig. 27b). To investigate the importance of CCL9 in TGF-β regulation of myeloid cell 
function, we overexpressed CCL9 in TβRII-deficient Gr-1+CD11b+ cells (Fig. 27c). 
Tumor cells showed increased survival and metastasis when co-injected with 
TβRII-deficient myeloid cells overexpressing CCL9 compared to vector control 
expression. Overexpression of CCL9 rescued the deficiency in TβRII-deficient myeloid 
cells and showed no difference with flox control myeloid cells (Fig. 27d). This result 
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strongly demonstrated that CCL9 was the key effector of myeloid TGF-β signaling to 
promote metastasis. 
 
Phosphorylated-p38 is a molecular mediator of the myeloid TGF-β pathway that 
regulates CCL9 expression 
We next examined the downstream mediators of the TGF-β pathway that might 
regulate CCL9 expression. Upon TGF-β treatment in vitro, a decreased level of P-p38 
and P-SMAD2 to a lesser extend, was observed in TβRII-deficient myeloid cells 
compared to that of wild type. However, this difference between TβRII-deficient and wild 
type myeloid cells was not observed in untreated conditions (Fig. 28a).  
To investigate the role of p38 in TGF-β regulation of CCL9 production, we cultured 
the floxed and TβRII-deficient Gr-1+CD11b+ cells in 4T1 tumor-conditioned media that 
contains high level of TGF-β. These cells were treated with the p38 inhibitor SB203580, 
which specifically inhibits p38 kinase activity, as shown by inhibited phosphorylation of 
ATF2, a target of P-p38 (Fig. 28b, right pannel). SB203580 reduced CCL9 production 
specifically in the control but not in TβRII-deficient Gr-1+CD11b+ cells (Fig. 28b, left 
pannel), suggesting P-p38 is critical in regulating TGF-β signaling and CCL9 expression 
in these immature myeloid cells. Additionally, p38 dominant negative Gr-1+CD11b+ 
cells showed a decreased CCL9 production compared to those cells from wild type mice 





Figure 26. Deletion of myeloid Tgfbr2 decreased lung metastasis and CCL9 
expression.  
(a) Lung metastasis of Tgfbr2Flox and Tgfbr2MyeKO mice (Pang et al., 2013). (b) Cytokine 
protein array indicating CCL9 expression in floxed or TβRII-deficient Gr-1+CD11b+ 
cells sorted from peripheral blood of 4T1 tumor-bearing Tgfbr2Flox and Tgfbr2MyeKO mice. 
The samples were combined from 2-3 mice, with duplicates for each sample. 
Semi-quantitative data of normalized dot density is shown on the left. (c) CCL9 ELISA 
of myeloid cells sorted from peripheral blood of multiple 4T1 tumor-bearing Tgfbr2Flox 
and Tgfbr2MyeKO mice. (d) CCL9 expression of Gr-1+CD11b+ cells when cultured in 4T1 
tumor-conditioned media with TGF-β neutralizing antibody 1D11 or control antibody 








Figure 27. CCL9 overexpression in TβRII-deficient Gr-1+CD11b+ cells rescued the 
phenotype of decreased tumor cell survival and increased tumor cell apoptosis.  
(a) SCVM for tumor cell survival. GFP labeled 67NR cells (5×105) were co-injected with 
floxed or TβRII-deficient Gr-1+CD11b+ cells (1×106). The lungs were taken out for 
imaging 1 and 6 hours after tail vein injection. Ten fields for each mouse lung were 
examined. Fluorescent signals at 6 hours were normalized to the 1 hour signal. n=3 mice 
per group. (b) TUNEL assay for tumor cell apoptosis from lung sections from (a). 
TUNEL positive cells were counted, calculated, and presented as percentages of GFP+ 
cells as shown at Y-axis. (c) ELISA showing overexpression of CCL9 in TβRII-deficient 
Gr-1+CD11b+ cells. (d) PUMA for tumor cell survival and metastasis. 67NR-GFP cells 
were co-injected with TβRII-deficient Gr-1+CD11b+ cells with or without CCL9 
overexpression. Fluorescence images were obtained 14 days after lung section culture. 
Fluorescence signal per field was quantified then normalized to the day 0 signal and 
presented as metastasis survival index. Three mice per group, 3-4 lung sections per 






Figure 28. P38 mediated TGF-β signaling to promote CCL9 expression.  
(a) Western bolts showing protein expressions of TβRII, P-p38, p38, P-SMAD2, and 
SMAD2 in TβRII-deficient Gr-1+CD11b+ cells compared to control cells. (b) Left panel: 
CCL9 ELISA of floxed or TβRII-deficient Gr-1+CD11b+ cells treated with the p38 
inhibitor SB203580 for 6 hours. Right panel: Western blots showing one of P-p38 target 
protein P-ATF, as evidence for the efficiency of the p38 inhibitor SB203580. (c) CCL9 
ELISA of floxed or TβRII-deficient Gr-1+CD11b+ cells treated with p38 inhibitor for 6 















TGF-β/p38 pathway regulates CCL9 expression 
Using Tgfbr2MyeKO mice, we detected a significantly lower CCL9 expression in 
TβRII-deficient compared to floxed control Gr-1+CD11b+ cells (Fig. 26). Other TGF-β 
family members were also reported to regulate CCL9 expression. For example, deletion 
of bone morphology protein receptor II (BMPRII) in mammary epithelial cells increased 
increased CCL9 expression (Owens et al., 2012), and one allele deletion of SMAD4 in 
colon epithelial cells significantly increased CCL9 expression (Kitamura et al., 2007). 
Our study was consistent with previous publications that TGF-β family members 
regulated CCL9 expression. 
We found that myeloid TGF-β promoted CCL9 expression, as deletion of TβRII in 
myeloid cells decreased CCL9 expression (Fig. 26). However, both previous publications 
stated that epithelial TGF-β signaling inhibited CCL9 expression, as deletion of BMPRII 
or one allele deletion of SMAD4 promoted CCL9 expression (Kitamura et al., 2007; 
Owens et al., 2012). The opposite TGF-β regulation of CCL9 expression in these two cell 
types was consistent with the fact that epithelial TGF-β inhibits metastasis, whereas 
myeloid TGF-β promotes metastasis. Activation of canonical SMAD-dependent or 
non-canonical SMAD-independent TGF-β downstream pathways might be one 
explanation for why myeloid TGF-β was tumor-promoting, whereas epithelial TGF-β 
was tumor-suppressing.  
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CCL9 expression was regulated by P-p38 in the non-canonical TGF-β pathway. 
Inhibition or knockdown of p38 blocked CCL9 expression (Fig. 28). This agreed with 
previous publications that p38 induced CCL9 by other factors, including fusion gene 
BCR-ABL, CpG oligodeoxynucleotides, and tumor necrosis factor-associated factor 6 
(Iotti et al., 2007; Ravindran et al., 2010; Yang et al., 2008b).  
 
CCL9 is an important effector in myeloid TGF-β function 
Chemokines have been implicated in TGF-β regulation of tumor microenvironment 
and tumor progression. Loss of TGF-β signaling in carcinoma cells enhances chemokine 
production and correlates with poor prognosis in human breast cancer (Massague, 2012). 
In mouse models, deletion of TGF-β signaling in cancer epithelial cells increases 
metastasis due to chemokine expression, which promotes the interaction of carcinoma 
cells and bone marrow derived cells, cell migration, decreases tumor cell apoptosis and 
increases tumor cell survival (Bierie and Moses, 2006; Ijichi et al., 2011).  
Our data demonstrated that CCL9 was the key regulator of the 
metastasis-promoting effects of myeloid TGF-β signaling, as overexpression of CCL9 in 
TβRII-deficient myeloid cells rescued tumor cell survival and metastatic capability (Fig. 
27). Our data also provided a new understanding of tumor-host interactions in TGF-β 





Targeting CCL9 for metastasis treatment may bypass the unwanted or adverse effect of 
TGF-β neutralization. 
Higher CCL9 expression either causes or correlates with higher metastasis. TGF-β 
signaling and biological functions are complex because of its dual roles, both as a tumor 
promoter and a suppresser. Thus, neutralization of TGF-β for cancer treatment may have 
adverse effects. A more feasible treatment might target the downstream effector CCL9, 
















SUMMARY AND CONCLUDING REMARKS 
 
Tumor-host interaction is indispensable for metastasis. A number of studies indicate 
that hematopoietic cells, especially myeloid cells play a fundamental role in forming a 
premetastatic niche (Hiratsuka et al., 2006; Kaplan et al., 2005). In parallel with these 
studies, we have found a significant increase in Gr-1+CD11b+ cells that are recruited into 
the premetastatic lung. These immature myeloid cells produce and secrete 
cytokines/chemokines to build up an inflammatory, proliferative, and tumor-favorable 
premetastatic microenvironment prior to tumor cell arrival at the secondary organ (Yan et 
al., 2010). The tumor-promoting effect of Gr-1+CD11b+ cells acts under the regulation 
of TGF-β signaling. Our previous study has revealed that distinct from other cell types, 
myeloid specific TGF-β is a tumor promoter, since deletion of TβRII significantly 
decreased metastasis (Pang et al., 2013). 
In this dissertation research, efforts have been made to understand how Gr-1+CDb+ 
cells in the premetastatic organ facilitate tumor cell metastasis. In particular, we 
investigate (1) whether this assistance is through cytokine/chemokine expression, (2) 
whether it promotes tumor cell survival as one the most important rate-limiting steps in 
metastasis, and (3) whether it is under TGF-β regulation. 
Using cytokine protein array screening, we found that CCL9 was significantly 
expressed and secreted by Gr-1+CD11b+ cells upon the co-culture with tumor cells, as 
well as in the premetastatic lung (Fig. 5, 6, and 8). CCL9 promoted tumor cell survival, 
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colonization and the resulting metastasis (Fig. 16, 20, 21, 23, and 24) through its only 
receptor CCR1 (Fig. 17 and 18). Mechanistically, CCL9 inhibited the PARP-dependent 
apoptosis pathway and promoted survival molecules including p-AKT and BCL-2 (Fig. 
24). Importantly, CCL9 mediated TGF-β signaling in myeloid cells to promote metastasis, 
as deletion of TβRII on Gr-1+CD11b+ cells significantly decreased CCL9 expression and 
lung metastasis (Fig. 26). The underlying molecular mechanism involved p38, since 
inhibition or deletion of p38 significantly decreased CCL9 expression (Fig. 28). The 
autocrine effect of CCL9/CCR1 further promoted CCL9 expression and the survival of 
Gr-1+CD11b+ cells (Fig. 25). Importantly, CCL23, the human orthologue of mouse 
CCL9, and its receptor CCR1, correlated with the clinical stage and progression of breast 
and lung cancers, indicating human relevance (Fig. 12 and 13).  
We report here the first time that CCL9 was significantly induced in immature 
myeloid cells in the premetastatic lung of tumor-bearing mice. It functioned as a tumor 
cell survival factor in the distant premetastatic site. CCL9 was also a critical downstream 
effector of the metastasis-promoting effect of myeloid-specific TGF-β signaling (Fig. 29).  
Our work suggests a novel cellular and molecular mechanism underlying the “seed 
and soil” hypothesis, and identifies a unique target that contributes to the rate-limiting 
step of cancer cell survival. Our work also provides a new understanding of tumor-host 
interaction in TGF-β regulation of metastasis, and uncovers a downstream molecule of 
the metastasis-promoting effect of myeloid TGF-β signaling. Targeting CCL9 derived 
from myeloid cells might be a way to reprogram the premetastatic organ 
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microenvironment and consequently inhibiting metastasis. Additionally, targeting CCL9 
as a downstream effector of the pro-metastatic myeloid TGF-β may overcome some of 















Figure 29. Schematic hypothesis. 
TGF-β produced by the primary tumor and myeloid cells signals through TβRII on 
myeloid cells to stimulate CCL9 production in myeloid cells (step# 1). CCL9 then signals 
through CCR1 on tumor cells and enhances tumor cell survival and metastatic colony 
formation (step# 2). CCL9 also signals through the CCR1 receptor on myeloid cells and 
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• Personally coordinate and communicate with collaborators from other labs to test scientific hypotheses. 
• Review, present, and report data at international conferences, including AACR Cellular Hetergeneity in 
the Tumor Microenvironment 2014, AACR Annual meeting 2013, and Cold Spring Harbor meeting 2012. 
 
Biochemistry/Developmental Biology Lab Class, Johns Hopkins University, Baltimore, MD 
Teaching Assistance (TA), Spring and Fall Semester 2009 - 2010  
• Develop, organize, and prepare experiments for undergraduate students. 
• Explain, review, and demonstrate each lab experiment to students. 
• Review and communicate with students about principles. Provide solution to any issues that may occur. 
• Coordinate and communicate with professors and TAs to review and evaluate lab reports/exams, as well 
as oversee and proctor exams. 
 
Li Yang Lab, LCBG, CCR, NCI, NIH, Bethesda, MD 
Cancer Research Training Award Trainee, 1/2009 - 9/2009 
• Develop, manage, coordinate, and conduct a research project that evaluates the host immunity in lung 
metastasis. 
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• Lead, coordinate, and conduct the establishment of a new lab. 
• Develop, prepare, present, prepare, and establish standard lab protocols. 
• Train, track, and oversee new postdoctoral fellows. 
• Evaluate, determine, recommend, order, prepare, track, and organize research equipment, reagents, and 
supplies. 
 
Harold Moses Lab, Vanderbilt University, Nashville, Vanderbilt-Ingram Cancer Center, TN 
Research Assistant, 2008 - 2009 
• Conduct, perform, and assist in a research project that evaluates the host immunity in lung metastasis. 
• Communicate and coordinate with research fellows and graduate students. 
• Report and present data in lab meetings. 
• Identify, recommend, and prepare samples, reagents, and documents for a new lab.   
 
Qing Wang Lab, Department of human genetics, HUST, China 
Undergraduate Thesis, 01/2007-06/2007 
• Manage, track, conduct, perform, evaluate and analyze an independent research project that successfully 
identifies a new human epilepsy mutation in one family by gene sequencing. 
• Coordinate, communicate, report, and present research progress and experimental data to thesis mentor. 
 
Robert L. McDonald Lab, Department of Neurology, Vanderbilt University, Nashville, TN 
Summer Internship, 07/2005-08/2005 and 07/2006-08/2006 
• Conduct, perform, evaluate, and analyze the effect of a new mutation in epilepsy. 
• Communicate, review, report, and present experimental data to lab manager. 
 
Awards and Honors 
• NIH Summer Research Mentor Award, NIH, 2014  
• Fellows Award for Research Excellence (FARE) and $1000 travel award, NIH, 2014 
• Cancer Research Training Award (CRTA), NIH, 2009 to present 
• Frist level Award for Undergraduate Dissertation Research, HUST, 2007 
• Honor of Merit from Dow Jones Newswires, 2006 
• Third level Award for HUST Undergraduate Students Thesis, HUST, 2005 
• Award and scholarship for research internship, HUST, 2005 
• Award and scholarship of Excellent Student Leader, HUST, 2003-2004 
• First level prize of College English stage play, HUST, 2003 
 
Publications 
Yan HH, Pang Y, Achyut BR, Lizard M, Hunter K, Khanna C, Hollander C, YangL. CCL9 induced by 
TGF-β signaling in myeloid cells enhances tumor cell survival in the premetastatic organ. Cancer 
Discovery. Rebuttal (IF: 15.929) 
Pang Y, Li Z, Gara S, Achyut B, Yan H, Day C, Weiss J, Wiltrout R, Trinchieri G, Morris J, Yang L. 
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Transforming growth factor beta signaling in myeloid cells is required for tumor metastasis. Cancer 
Discovery. 2013 Aug;3(8):936-51. (IF: 15.929) 
Yan HH, Pickup M, Pang Y, Gorska AE, Li Z, Chytil A, Geng Y, Gray JW, Moses HL, Yang L. 
Gr-1+CD11b+ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic 
lung. Cancer Research. 2010 Aug 1;70(15):6139-49. (IF: 9.284) 
 
Professional Associate 
• American Association of Cancer Research (AACR), 2009 – present 
• Social of Chinese Bioscientists in America (SCBA), 2012- present 
 
Other Activities 
• Lab management 2009-present. Track, identify, and order supplies. Manage equipment. Organize 
meetings. 
• Judge for FARE 2015 Travel Award Competition 2014. Review, evaluate, and determine top research 
abstracts. 
• Organizer for LCBG Annual celebration 2012-2014. Organize, prepare, and conduct activities. 
• Member of graduate student council (GSC) 2009-2010. Organize seminars as a Thesis Committee 
member. 
• Member of VUCSSA (Vanderbilt University Chinese Students and Scholars Association) 
2007-2008. Lead, organize, coordinate, and prepare 2008 Beijing Olympic Festival and 2008 Chinese New 
Year Festival. 
• Leader of college student union 2003-2006. Coordinate, organize, and conduct college activities. 
• Leader of class 2003-2007. Lead, coordinate, and organize class meetings and activities. Plan and 
organize a trip of 14 classmates to a village in western China to teach primary school students.  
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